<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title>PLoS ONE</journal-title><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">08-PONE-RA-07084R2</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0005153</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Neuroscience/Neurodevelopment</subject><subject>Neuroscience/Neuronal Signaling Mechanisms</subject><subject>Diabetes and Endocrinology/Endocrinology</subject></subj-group></article-categories><title-group><article-title>Estradiol Activates &#x003b2;-Catenin Dependent Transcription in Neurons</article-title><alt-title alt-title-type="running-head">Estradiol Modulates &#x003b2;-Catenin</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Varea</surname><given-names>Olga</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Garrido</surname><given-names>Juan Jose</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Dopazo</surname><given-names>Ana</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mendez</surname><given-names>Pablo</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Garcia-Segura</surname><given-names>Luis Miguel</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wandosell</surname><given-names>Francisco</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Centro de Investigaci&#x000f3;n Biom&#x000e9;dica en Red sobre Enfermedades Neurodegenerativas (CIBERNED) and Centro de Biolog&#x000ed;a Molecular &#x0201c;Severo Ochoa&#x0201d;, CSIC-UAM, Madrid, Spain</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Genomics Unit, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Laboratory of Neuroactive Steroids, Instituto Cajal, CSIC, Madrid, Spain</addr-line></aff><aff id="aff4"><label>4</label><addr-line>Laboratory of Neuronal Polarity, Instituto Cajal, CSIC, Madrid, Spain</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Mei</surname><given-names>Lin</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">Medical College of Georgia, United States of America</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>fwandosell@cbm.uam.es</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: JJG PM LMGS FGW. Performed the experiments: OV AD PM. Analyzed the data: OV JJG AD LMGS FGW. Contributed reagents/materials/analysis tools: AD. Wrote the paper: FGW.</p></fn></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>10</day><month>4</month><year>2009</year></pub-date><volume>4</volume><issue>4</issue><elocation-id>e5153</elocation-id><history><date date-type="received"><day>29</day><month>10</month><year>2008</year></date><date date-type="accepted"><day>17</day><month>2</month><year>2009</year></date></history><copyright-statement>Varea et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement><copyright-year>2009</copyright-year><abstract><p>Estradiol may fulfill a plethora of functions in neurons, in which much of its activity is associated with its capacity to directly bind and dimerize estrogen receptors. This hormone-protein complex can either bind directly to estrogen response elements (ERE's) in gene promoters, or it may act as a cofactor at non-ERE sites interacting with other DNA-binding elements such as AP-1 or c-Jun. Many of the neuroprotective effects described for estrogen have been associated with this mode of action. However, recent evidence suggests that in addition to these &#x0201c;genomic effects&#x0201d;, estrogen may also act as a more general &#x0201c;trophic factor&#x0201d; triggering cytoplasmic signals and extending the potential activity of this hormone. We demonstrated that estrogen receptor alpha associates with &#x003b2;-catenin and glycogen synthase kinase 3 in the brain and in neurons, which has since been confirmed by others. Here, we show that the action of estradiol activates &#x003b2;-catenin transcription in neuroblastoma cells and in primary cortical neurons. This activation is time and concentration-dependent, and it may be abolished by the estrogen receptor antagonist ICI 182780. The transcriptional activation of &#x003b2;-catenin is dependent on lymphoid enhancer binding factor-1 (LEF-1) and a truncated-mutant of LEF-1 almost completely blocks estradiol TCF-mediated transcription. Transcription of a TCF-reporter in a transgenic mouse model is enhanced by estradiol in a similar fashion to that produced by Wnt3a. In addition, activation of a luciferase reporter driven by the <italic>engrailed</italic> promoter with three LEF-1 repeats was mediated by estradiol. We established a cell line that constitutively expresses a dominant-negative LEF-1 and it was used in a gene expression microarray analysis. In this way, genes that respond to estradiol or Wnt3a, sensitive to LEF-1, could be identified and validated. Together, these data demonstrate the existence of a new signaling pathway controlled by estradiol in neurons. This pathway shares some elements of the insulin-like growth factor-1/Insulin and Wnt signaling pathways, however, our data strongly suggest that it is different from that of both these ligands. These findings may reveal a set of new physiological roles for estrogens, at least in the Central Nervous System (CNS).</p></abstract><counts><page-count count="24"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Estrogens fulfill a wide range of functions during development and differentiation in mammals of both sexes. In addition to these functions, they are also thought to play an important role in neuroprotection <xref ref-type="bibr" rid="pone.0005153-Wang1">&#x0005b;1&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005153-Wise1">&#x0005b;3&#x0005d;</xref>. The actions of estrogens have been classified as either &#x0201c;genomic actions&#x0201d; or &#x0201c;non-genomic, rapid actions&#x0201d;. The genomic actions are based on the capacity of the estrogen receptors (ERs) to bind to co-activators or co-repressors in order to enhance or inhibit the transcription of target genes, and it has been reported in many cell types (reviewed in <xref ref-type="bibr" rid="pone.0005153-McKenna1">&#x0005b;4&#x0005d;</xref>). This activity involves the dimerization of two receptor molecules mediated by the presence of the hormone and the generation of a macromolecular complex with co-regulators (reviewed in <xref ref-type="bibr" rid="pone.0005153-Beato1">&#x0005b;5&#x0005d;</xref>). The ERs belong to the nuclear receptor superfamily and two receptors, alpha and beta, have been identified (NR3A1 and NR3A2, according to the nomenclature of the NRN Committee <xref ref-type="bibr" rid="pone.0005153-Kuiper1">&#x0005b;6&#x0005d;</xref>. The structure of both receptors is similar containing a highly homologous DNA-binding region (95&#x00025;) and a hormone binding region with weaker homology (69&#x00025;), whereas the carboxy and amino-terminal regions are the most divergent regions (58&#x00025; homology, reviewed in <xref ref-type="bibr" rid="pone.0005153-Beato2">&#x0005b;7&#x0005d;</xref>). Apart from this genomic action, estrogen can trigger rapid &#x0201c;non-genomic signaling&#x0201d; associated with the activation of second messengers. Among these, the activation of the mitogen activated protein kinase (MAPK) <xref ref-type="bibr" rid="pone.0005153-Singh1">&#x0005b;8&#x0005d;</xref>, protein kinase C (PKC) <xref ref-type="bibr" rid="pone.0005153-Cordey1">&#x0005b;9&#x0005d;</xref> and phosphoinositide 3-kinase (PI3K) <xref ref-type="bibr" rid="pone.0005153-Honda1">&#x0005b;10&#x0005d;</xref> signaling pathways has been described. Indeed, cooperation with insulin-like growth factor-1 (IGF-1) has been demonstrated and ER&#x003b1; has been reported to associate with p85, the regulatory subunit of PI3K <xref ref-type="bibr" rid="pone.0005153-Mendez1">&#x0005b;11&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005153-CardonaGomez1">&#x0005b;12&#x0005d;</xref>. Furthermore, estrogens may also act in a ligand-independent manner <xref ref-type="bibr" rid="pone.0005153-Demay1">&#x0005b;13&#x0005d;</xref> and they may exert certain antioxidant effects that are independent of their receptors.</p><p>We recently demonstrated that ER&#x003b1; is linked to PI3K associated &#x0201c;cytoplasmic signaling&#x0201d; in the brain and in primary neurons, where estradiol can induce the immediate activation of Akt/PKB and the subsequent inhibition of glycogen synthase kinase 3 (GSK3). On the light of the important role proposed for GSK3 in neuronal survival <xref ref-type="bibr" rid="pone.0005153-Pap1">&#x0005b;14&#x0005d;</xref> and in neuropathologies such as amyloid neurotoxicity <xref ref-type="bibr" rid="pone.0005153-Xu1">&#x0005b;15&#x0005d;</xref>, the role of this new estradiol signaling pathway merits further analysis.</p><p>We also identified novel complexes in which ER&#x003b1;, GSK3 and &#x003b2;-catenin were associated, demonstrating that the action of estradiol transiently stabilized &#x003b2;-catenin, which is disassociated from the complex with ER&#x003b1; <xref ref-type="bibr" rid="pone.0005153-CardonaGomez1">&#x0005b;12&#x0005d;</xref>. The stabilization of &#x003b2;-catenin has been related with different functions of this protein. In addition to act in cell-cell adhesion, &#x003b2;-catenin also serves as a co-transcriptional regulator, modulating the functions of the T cell factor (TCF)/ lymphoid enhancer binding factor (LEF) proteins that are closely associated with Wnt signaling (reviewed in <xref ref-type="bibr" rid="pone.0005153-Moon1">&#x0005b;16&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005153-Barolo1">&#x0005b;19&#x0005d;</xref>). Hence, the stabilization of &#x003b2;-catenin by estradiol may also have effects on gene transcription.</p><p>In this study we have assessed whether the &#x003b2;-catenin, stabilized by estradiol in neurons, may exert a significant effect at the transcriptional level. We show that the stabilization of &#x003b2;-catenin by estradiol is correlated with the inhibition of GSK3 in neuronal-like cells (N2a-m), as well as in cortical neurons. Indeed, estradiol increased TCF/LEF-1 transcription in a dose-dependent manner. This increase in transcription was partially prevented by the addition of an estradiol antagonist and was mimicked by an alpha and beta specific-agonist. In neuronal cells, estradiol induced the formation of a TCF-DNA complex that was impaired by the presence of antibodies against LEF-1. Moreover, in cortical neurons from a TCF/LEF-1&#x02013;&#x003b2;gal transgenic mouse, &#x003b2;-galactosidase activity was up-regulated by the action of estradiol. Finally, in a LEF-1 mutant cell line, we identified some genes that were differentially regulated by estradiol.</p><p>Together, all these data demonstrate that in addition to its nuclear action mediated through the ER, estradiol triggers a signal that recruits &#x003b2;-catenin and LEF-1 and that may be responsible for more wide-ranging actions of this hormone, at least in neurons.</p></sec><sec id="s2"><title>Results</title><sec id="s2a"><title>Estradiol transiently regulates the phosphorylation of GSK3 and the amount of &#x003b2;-catenin in N2a-m neuronal cells and cortical neurons</title><p>We recently demonstrated that estradiol inhibit GSK3 and stabilize &#x003b2;-catenin in the hippocampus and in hippocampal neurons. To further analyze this phenomenon, it was necessary to transfect neuronal cells. We first examined whether neuroblastoma cells behave like primary neurons concerning this estrogenic action. We found that <bold>N2a-m</bold> cells, a clone derived from NB2a (ATCC: CCL 131) and that has been maintained for several years in our laboratory, responded to estradiol in a similar manner as primary neurons, as demonstrated below.</p><p>The effect of estradiol on this cell line was examined and we initially determined whether N2a-m cells expressed both &#x003b1; and &#x003b2; estrogen receptors when maintained in serum&#x02013;free medium (Supplementary <xref ref-type="supplementary-material" rid="pone.0005153.s001">Figure S1</xref>). When N2a-m cells were exposed to estradiol, ER&#x003b1;-immunoreactivity became more concentrated in the nucleus in a time and dose dependent manner (Supplementary <xref ref-type="supplementary-material" rid="pone.0005153.s001">Figure S1</xref>). Thus, since these cells respond to estradiol and can be efficiently transfected, we analyzed whether exposure to estradiol could modify GSK3&#x003b2;-PSer using primary cortical neurons as a reference in parallel. Immunoreactivity against GSK3&#x003b2;-PSer was increased in N2a-m cells exposed to estradiol, reaching a maximum (5&#x000b1;1 fold, n&#x0200a;&#x0003d;&#x0200a;4) 60&#x02013;90 minutes after the addition of the hormone (<xref ref-type="fig" rid="pone-0005153-g001">Figure 1A</xref>). A similar time-course of GSK3&#x003b2;-PSer immunoreactivity was observed in cortical primary neurons (<xref ref-type="fig" rid="pone-0005153-g001">Figure 1C</xref>), reaching a maximum increase (2.2&#x000b1;0.5 fold; n&#x0200a;&#x0003d;&#x0200a;3) 90 minutes after exposure to the hormone. The increase in serine phosphorylation of GSK3&#x003b2; was dose-dependent and was maximal in the range of 100 to 200 nM (2.5&#x000b1;0.5 fold; n&#x0200a;&#x0003d;&#x0200a;3, <xref ref-type="fig" rid="pone-0005153-g001">Figure 1A</xref>).</p><fig id="pone-0005153-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005153.g001</object-id><label>Figure 1</label><caption><title>Treatment of estradiol increases Ser<sup>9,21</sup>-GSK3 phosphorylation and &#x003b2;-catenin accumulation in neuronal cells.</title><p>(A)-Neuroblastoma N2a-m were treated with different doses of estradiol and for different times (20&#x02013;120 min with 10&#x02013;500 nM) and the maximum increase in GSK3&#x003b2;-PSer<sup>9</sup> was observed when they were treated for 60 min with 100&#x02013;200 nM estradiol. (B)- Stabilization of &#x003b2;-catenin. N2a-m cells treated with estradiol showed a clear increase in &#x003b2;-catenin that could be prevented by prior exposure to ICI 182780 (used 100&#x000d7; concentrated in comparison to estradiol), 60 minutes before estradiol treatment (lower panel). (C)-Cortical Primary Neurons (2DIV) were treated with estradiol (100 nM) and the maximum increase in GSK3&#x003b2;-PSer<sup>9</sup> and the subsequent stabilization of &#x003b2;-catenin was clearly detected 60&#x02013;90 min after the onset of exposure. In all cases diagram shows the mean normalized densitometry values and the corresponding standard deviations from at least three independent experiments. Asterisks indicate statistical significance (Student's t-test) &#x0002a;&#x0002a; (P&#x02264;0.05), &#x0002a; (P&#x02264;0.01). The single &#x0002a; or &#x0002a;&#x0002a; compares data to control whereas the bar between different points shows statistical differences between experimental values.</p></caption><graphic xlink:href="pone.0005153.g001"/></fig><p>The second important element in our analysis is &#x003b2;-catenin, as demonstrated in hippocampal neurons <xref ref-type="bibr" rid="pone.0005153-CardonaGomez1">&#x0005b;12&#x0005d;</xref>. Thus, we determined whether inhibition of GSK3 was correlated with the stabilization of &#x003b2;-catenin in cell extracts from N2a-m and cortical neurons treated with estradiol (100 nM). The total amount of &#x003b2;-catenin increased in both N2a-m cells (3.5&#x000b1;0.5 fold; n&#x0200a;&#x0003d;&#x0200a;3) (<xref ref-type="fig" rid="pone-0005153-g001">Figure 1A</xref>) and cortical neurons (2.2&#x000b1;0.3 folds, n&#x0200a;&#x0003d;&#x0200a;3) (<xref ref-type="fig" rid="pone-0005153-g001">Figure 1C</xref>), with a time-course similar to that of the changes in GSK3-PSer (<xref ref-type="fig" rid="pone-0005153-g001">Figure 1 A and B</xref>). The increase in the stabilization of &#x003b2;-catenin by estradiol was prevented by ICI 182780, a specific ER receptor antagonist (<italic>ICI/estradiol ratio was maintained 100&#x000d7;</italic>) (<xref ref-type="fig" rid="pone-0005153-g001">Figure 1B</xref>).</p><p>A complex of ER &#x003b1; and &#x003b2;-catenin was recently detected in the hippocampus of female ovariectomized rats <xref ref-type="bibr" rid="pone.0005153-CardonaGomez1">&#x0005b;12&#x0005d;</xref>. We assessed whether a similar complex was present in extracts from N2a-m cells. Our data showed that &#x003b2;-catenin was detected in complexes immunoprecipitated with antibodies against ER&#x003b1; or ER&#x003b2; (<xref ref-type="fig" rid="pone-0005153-g002">Figure 2</xref>). Similarly, both GSK3&#x003b1; and &#x003b2; were detected in these complexes, although there was less GSK3 recovered when antibodies against ER&#x003b1; were used. As a positive control in these experiments, material was immunopreciptated with an antibody against Adenomatous Polyposis Coli protein (APC) and in these latter experiments, mostly GSK3&#x003b2; was detected (<xref ref-type="fig" rid="pone-0005153-g002">Figure 2</xref>).</p><fig id="pone-0005153-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005153.g002</object-id><label>Figure 2</label><caption><title>Estrogen receptors form a complex with &#x003b2;-catenin and GSK3 in N2a-m cells.</title><p>ER&#x003b1; and ER&#x003b2; were immunoprecipitated from N2a-m cells, and similar endogenous protein complexes were observed with both antibodies. Immunoprecipitation with an anti-APC antibody is shown as an internal control of a &#x003b2;-catenin interacting protein. Both GSK3 isoforms were detected in the immunocomplex recovered with ER&#x003b1; or ER&#x003b2; antibodies, whereas GSK3&#x003b2; is the major isoform recovered with APC antibodies, used as a positive control. The immunoprecipitation also shows a fraction of &#x003b2;-catenin associated with both ER isoforms. IgG's represent the IP using irrelevant IgGs as a negative control.</p></caption><graphic xlink:href="pone.0005153.g002"/></fig></sec><sec id="s2b"><title>Estradiol increase the association of &#x003b2;-catenin to the neuronal membrane fraction</title><p>Given that &#x003b2;-catenin may fulfill two distinct cellular functions, as an adhesion molecule or as co-transcription factor. Two different pools have been described associated with different functions <xref ref-type="bibr" rid="pone.0005153-Moon1">&#x0005b;16&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005153-Bienz1">&#x0005b;20&#x0005d;</xref>. Thus, we determined whether estradiol-mediated stabilization augmented either of the putative &#x003b2;-catenin pools. Membrane and nuclear fractions were obtained from cultured neurons exposed to the hormone for 30 and 60 minutes. Interestingly, the amount of &#x003b2;-catenin detected in the membrane fraction was increased at 30 and 60 minutes after exposure to estradiol whereas the nuclear fraction was almost unaffected (Supplementary <xref ref-type="supplementary-material" rid="pone.0005153.s002">Figure S2</xref>).</p></sec><sec id="s2c"><title>Estradiol activates TCF-mediated transcription</title><p>Even though accumulation of &#x003b2;-catenin in the cell nucleus could not be perceived at the biochemical level, we assessed whether estradiol might induce &#x003b2;-catenin mediated transcriptional activation. For this purpose we transfected N2a-m cells with a TCF-luciferase reporter (TOPFlash) in combination with an EGFP reporter. When estradiol (100 nM) was added after cell transfection, luciferase activity increased 24&#x000b1;4 fold (n&#x0200a;&#x0003d;&#x0200a;4, <xref ref-type="fig" rid="pone-0005153-g003">Figure 3D</xref>), reaching a maximum 60&#x02013;90 minutes after hormonal exposure (<xref ref-type="fig" rid="pone-0005153-g003">Figure 3A</xref>). The estradiol-induced increase in luciferase activity was time and concentration-dependent (<xref ref-type="fig" rid="pone-0005153-g003">Figure 3A&#x02013;B</xref>). Moreover, the transcriptional activity depended on ERs since it was drastically reduced when the ER antagonist ICI 182780 was applied in conjunction with estradiol (<xref ref-type="fig" rid="pone-0005153-g003">Figure 3C</xref>). In parallel, when we transfected N2a-m cells with a mutated form of the TCF reporter (FOPFlash) we were unable to detect <italic>luciferase</italic> activity (<xref ref-type="fig" rid="pone-0005153-g003">Figure 3C</xref>).</p><fig id="pone-0005153-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005153.g003</object-id><label>Figure 3</label><caption><title>Estradiol augments TCF/LEF-dependent transcription in N2a-m cells.</title><p>N2a-m cells were transfected with the TOPFlash or FOPFlash reporter plasmid with EGFP-pCDNA3, and the cells were then treated with estradiol and other test compounds for the different times and at the different concentrations indicated. (A&#x02013;B), Soluble extracts from estradiol treated cells were obtained and <italic>luciferase</italic> activity was measure as indicated in the <xref ref-type="sec" rid="s4">Methods</xref>. The normalized data were expressed in relative light units (RLU) compared to the control solvent, and the response was maximal at 60 min using 100 nM. (C).The effect of estradiol can be prevented by prior exposure to the ER antagonist ICI 182780 10 &#x000b5;M for 2 hr. (D), Specific agonists of each estrogen receptor (PPT: ER&#x003b1; agonist, and DPN: ER&#x003b2; agonist, at two concentrations, 5 and 10 nM) also induced TCF/LEF-mediated transcription although PPT was more efficient than DPN. The graphs show the normalized <italic>luciferase</italic> activity from at least three independent experiments. The P value from the Student's t-test was &#x0002a; (P&#x02264;0.05), &#x0002a;&#x0002a; (P&#x02264;0.01). The single &#x0002a; or &#x0002a;&#x0002a; compares data to control whereas the bar between different points shows statistical differences between them.</p></caption><graphic xlink:href="pone.0005153.g003"/></fig><p>To determine whether this transcriptional activation was associated with ER &#x003b1; or ER &#x003b2;, we used two specific agonists of either the &#x003b1; or &#x003b2; receptor isoforms. Both 4,4&#x02032;,4&#x02033;-(propyl-&#x0005b;(1)H&#x0005d;-pyrazole-1,3,5-triyl) trisphenol (PPT, &#x003b1;-selective) and 2,3-bis (4-hydroxyphenyl) propionitrile (DPN (&#x003b2;-selective) agonists increased transcriptional activity in N2a-m cells, although the activity mediated by PPT was more prominent that that mediated by DPN, suggesting that ER &#x003b1; is more effectively coupled to this novel pathway (<xref ref-type="fig" rid="pone-0005153-g003">Figure 3D</xref>). As a positive control of this TCF-reporter, we took advantage of the fact that this neuronal cell responds to some Wnt proteins and thus, &#x003b2;-catenin stabilization was detected when N2a-m cells were exposed to Wnt3a (Supplementary <xref ref-type="supplementary-material" rid="pone.0005153.s003">Figure S3</xref>). When we exposed cells to Wnt3a after TOPFlash transfection, the transcriptional activation obtained in response to Wnt3a was similar to that obtained after estradiol treatment (Supplementary <xref ref-type="supplementary-material" rid="pone.0005153.s003">Figure S3</xref>).</p></sec><sec id="s2d"><title>The expression of a TCF-&#x003b2;-galactosidase reporter, as well as an engrailed-1 promoter luciferase reporter, is modulated by estradiol in primary neurons</title><p>To determine whether estradiol can regulate the expression of a reporter controlled by TCF in primary neurons, we used two complementary approaches. First, we transfected TOPFlash or FOPFlash into primary neurons (<xref ref-type="fig" rid="pone-0005153-g004">Figure 4A</xref>) and after TOPFlash transfection, we detected an increase in luciferase activity (4.8&#x000b1;1.2 folds; n&#x0200a;&#x0003d;&#x0200a;3) in the presence of estradiol (100 nM), which was not induced after FOPFlash transfection (<xref ref-type="fig" rid="pone-0005153-g004">Figure 4A</xref>). High concentrations of insulin (ITS supplements) also produced a 10-fold increase in these cells as a positive control (<xref ref-type="fig" rid="pone-0005153-g004">Figure 4A</xref>). In a second approach, we obtained primary cultures of cortical neurons from TCF-&#x003b2;gal transgenic mice, a colony designed to analyze the activation of the Wnt pathway in vivo <xref ref-type="bibr" rid="pone.0005153-DasGupta1">&#x0005b;21&#x0005d;</xref>. We detected &#x003b2;-galactosidase expression in almost all cortical neurons of TCF-&#x003b2;gal transgenic mice (<xref ref-type="fig" rid="pone-0005153-g004">Figure 4B</xref>) and thus, we analyzed the amount of &#x003b2;-galactosidase after exposure to either estradiol or Wnt3a. Both estradiol and Wnt3a produced a similar moderate increase in &#x003b2;-galactosidase, assessed in western blots (<xref ref-type="fig" rid="pone-0005153-g004">Figure 4B</xref>). This finding was confirmed by quantitative RT-PCR in parallel experiments. Hence, in total RNA obtained from cultured cortical neurons, a similar increase in the expression of the LacZ-transgene was detected by RealTime RT-PCR after exposure to Wnt3a or estradiol when normalized to actin mRNA expression (<xref ref-type="fig" rid="pone-0005153-g004">Figure 4C</xref>).</p><fig id="pone-0005153-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005153.g004</object-id><label>Figure 4</label><caption><title>Estradiol increase TCF/LEF-dependent transcription in cortical neurons.</title><p>(A)-Cortical neurons from E18 embryos were nucleofected with TOPFlash or FOPFlash reporter plasmids and luciferase activity was analyzed after 2DIV. Estradiol treatment (60 min, 100 nM) selectively increased transcription from the TOPFlash reporter plasmid compared to FOPFlash, which shows no activity. Insulin treatment (5 &#x000b5;g/ml) was used as a control of induction. (B&#x02013;C)- Expression of the LacZ gene in response to estradiol in transgenic mice. The scheme represents the lacZ transgene under the control of three consensus TCF/LEF-binding motifs upstream of the c-fos promoter, as described in <xref ref-type="sec" rid="s4"><italic>Materials and Methods</italic></xref>. (B)-Upper panel. Total extracts of cortical neurons (2DIV) were obtained from a TCF/LEF-lacZ transgenic mouse (see <xref ref-type="sec" rid="s4">Materials and Methods</xref>) and the &#x003b2;-galactosidase (&#x003b2;-gal) expression was assessed in western blots after estradiol treatment (100&#x02013;200 nM) for 3 h. Wnt3a (20 ng/ml) was used as a control of TCF-mediated induction. A slight increase in &#x003b2;-gal protein was observed after exposure to estradiol, as with recombinant Wnt3a protein. (B), Lower panel. Basal expression of &#x003b2;-galactosidase in neurons from transgenic mice was assessed by immunocytochemistry using specific antibodies against &#x003b2; galactosidase (green) and Phalloidin-labelled with Alexas 549. (C), Alternatively, after treatment with estradiol or Wnt3a, total Lac Z expression was quantified by RT-PCR using specific &#x003b2;-gal oligonucleotides and using actin (a housekeeping gene) as an internal standard (see <xref ref-type="sec" rid="s4"><italic>Methods</italic></xref>). The amplification of both genes was analyzed on agarose gels and the graph represents the normalized data obtained from the Lightcycler analysis. Both treatments clearly increase transcriptional activity when compared to controls.</p></caption><graphic xlink:href="pone.0005153.g004"/></fig><p>As a complementary alternative we try to analyze whether an endogenous promoter may be regulated by estradiol in a similar fashion as Wnt3a. For that purpose we used a construct containing a 2.8 Kb region of the Engrailed-1 promoter that has three LEF-1 sites situated upstream of a luciferase gene pENP1<italic>Luc</italic><xref ref-type="bibr" rid="pone.0005153-McGrew1">&#x0005b;22&#x0005d;</xref> (see scheme in <xref ref-type="fig" rid="pone-0005153-g005">Figure 5A</xref>). Again luciferase expression was clearly driven by estradiol, although at identical amounts of cDNA the response of TOPFlash was more potent (<xref ref-type="fig" rid="pone-0005153-g005">Figure 5B</xref>).</p><fig id="pone-0005153-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005153.g005</object-id><label>Figure 5</label><caption><title>The engrailed 1-<italic>luciferase</italic> construct responds to estradiol.</title><p>The scheme represents the structure of the 2.8 kB of construct containing the proximal region of endogenous <italic>engrailed</italic> 1 promoter bind to luciferase reporter. N2a-m cells were transfected with the pENP1-luciferase reporter plasmid (<italic>250</italic>, <italic>200 and 750 ng</italic>) (represented as 0.25, 0.5, 0.75), which contains three LEF-1 sites (see upper panel). The Lower panel shows a comparison of the induction of TOPFlash (<italic>750 ng</italic>) and pENP-luc in this cell line. Although basal levels of luciferase activity are lower in the pENP1-luc reporter plasmid, estradiol induces this activity to 3-fold that of the control levels, as shown in the right panel. The graph in B shows the normalized <italic>luciferase</italic> activity from at least three independent experiments. The P value from the Student's t-test was &#x0002a;&#x0002a; (P&#x02264;0.01) when compared with control data.</p></caption><graphic xlink:href="pone.0005153.g005"/></fig></sec><sec id="s2e"><title>Does estradiol use a &#x003b2;-catenin/TCF transcription system similar to that used by Wnt?</title><p>The mechanism by which Wnt modulates &#x003b2;-catenin-mediated transcription is sensitive to the phosphorylation of &#x003b2;-catenin as well as to &#x003b2;-catenin/TCF binding (reviewed in <xref ref-type="bibr" rid="pone.0005153-Mulholland1">&#x0005b;17&#x0005d;</xref>). Thus, when we transfected N2a-m cells with different amounts of a constitutively active mutant of &#x003b2;-catenin (S33Y), the transcriptional activity in extracts of these cells was almost maximal and it was virtually insensitive to the addition of estradiol (15&#x02013;20&#x00025;), when compared with 5&#x02013;12 folds induction (control or mock-transfected cells <italic>versus</italic> estradiol) (<xref ref-type="fig" rid="pone-0005153-g006">Figure 6A</xref><italic>versus</italic><xref ref-type="fig" rid="pone-0005153-g003">Figure 3B&#x02013;C</xref>). In all these experiments, the total amount of &#x003b2;-catenin after transfection and treatment was controlled to ensure that it did not influence the results (<xref ref-type="fig" rid="pone-0005153-g006">Figure 6B</xref>). Hence, these data strongly suggested that estradiol-mediated transcription requires the formation of a &#x003b2;-catenin/TCF complex. Indeed, when a version of LEF-1 that is truncated in the &#x003b2;-catenin binding region (&#x00394;56LEF-1) <xref ref-type="bibr" rid="pone.0005153-Hsu1">&#x0005b;23&#x0005d;</xref> was transiently transfected into N2a-m neuroblastoma cells in combination with TOPFlash, estradiol did not drive <italic>luciferase</italic> expression (<xref ref-type="fig" rid="pone-0005153-g006">Figure 6C</xref>), whereas N2a-m-<italic>mock</italic> transfected cells responded to estradiol as previously shown.</p><fig id="pone-0005153-g006" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005153.g006</object-id><label>Figure 6</label><caption><title>Interaction of &#x003b2;-catenin/LEF-1 mediates the transcriptional capacity of estradiol.</title><p>(A)-&#x003b2;-catenin/TCF estradiol-mediated transcription depends on the phosphorylation of &#x003b2;-catenin. N2a-m cells were transfected with different amounts of the S33Y-&#x003b2;catenin (S33Y-&#x003b2;cat) expression plasmid as indicated (<italic>250 or 500 ng</italic>). (B)-&#x003b2;-catenin levels in total extracts from cells transfected with S33Y-&#x003b2;cat or the empty cDNA3.1 plasmid, representative of the analysis of lanes (0.5&#x0002b;); and (0.5&#x02212;) in A. Under the high levels of S33Y-&#x003b2;cat expression estradiol was virtually unable to further induce reporter expression. No statistical differences are founded between the bars data from different experiments. (C)-Interaction of &#x003b2;-catenin with TCFs is essential for estradiol to induce gene transcription through TCF sites. Endogenous LEF-1 protein levels remain unchanged after estradiol treatment for 60&#x02013;90 min, as seen with the anti-N terminal LEF-1 antibody. Expression of the &#x00394;56LEF-1 protein was detected in western blots after transfection of increasing amounts of plasmid (<italic>400 or 600 ng</italic>) using an antibody against the HMG box region of LEF-1. The overexpression of a LEF-1 mutant construct (&#x00394;56LEF-1) prevents estradiol from inducing expression from the TOPFlash reporter plasmid when compared with <italic>mock</italic>-transfected cells. (D)-&#x00394;56LEF-1 reduces estradiol induced luciferase expression from pENP1<italic>-luc</italic>. The overexpression of &#x00394;56LEF-1 construct reduced the luciferase activity induced by estradiol from the pENP1-Luc plasmid, when compared with <italic>mock</italic>-transfected cells (<italic>empty</italic>-pcDNA3). Estradiol (E) induced luciferase activity to 8&#x02013;15 fold that of the control levels (C and E), in the pENP1-luc reporter. However, the expression of &#x00394;56LEF-1 diminished this induction (compare pCDNA3&#x0002b;E <italic>versus</italic> &#x00394;56&#x0002b;E). In both cases (C&#x02013;D), the graphs show the normalized <italic>luciferase</italic> activity (RLU) from at least three independent experiments. The P value from the Student's t-test was &#x0002a; (P&#x02264;0.05).</p></caption><graphic xlink:href="pone.0005153.g006"/></fig><p>Similarly, when we transiently transfected into N2a-m neuroblastoma cells with &#x00394;56LEF-1 in combination with pENP1 <italic>Luc</italic>, the <italic>luciferase</italic> expression estradiol-mediated was severely reduced by the expression of LEF1-mutant (<xref ref-type="fig" rid="pone-0005153-g006">Figure 6D</xref>).</p></sec><sec id="s2f"><title>Are &#x003b2;-catenin/TCF-DNA complexes activated by estradiol?</title><p>To determine whether the estradiol-mediated transcriptional activation detected in our study relies on similar complexes to those described for Wnt, we assayed the DNA-protein complexes with TCF-binding sequence in nuclear extracts from N2a-m cells (<italic>EMSA assay</italic>). We detected a DNA-protein complex that was more evident after estradiol or Wnt3a treatment (<xref ref-type="fig" rid="pone-0005153-g007">Figure 7</xref>). Moreover, the formation of this complex was impaired by pre-incubation with the ER antagonist ICI 182780 and the detection of the complex could be competed with unlabelled TCF-oligonucleotide but not by a mutant TCF oligonucleotide (<xref ref-type="fig" rid="pone-0005153-g007">Figure 7 A</xref>).</p><fig id="pone-0005153-g007" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005153.g007</object-id><label>Figure 7</label><caption><title>The LEF-1-DNA complex is detected in nuclear protein extracts and it is modulated by estradiol.</title><p>(A)-Identification of the specific band by competition with non-labeled wt oligonucleotides. Nuclear proteins were obtained from N2a-m cells treated for 30 minutes with estradiol, ICI or Wnt3a, enabling specific TCF-DNA complexes to be detected. In control nuclear extracts the presence of a pre-established TCF-DNA complex was detected, which augmented slightly in the presence of estradiol and that decreased upon ICI treatment. The arrow indicates the complex. (B)-Analysis of the identity of the TCF-DNA complex. Antibodies against TCF1, LEF-1, or irrelevant IgGs (C) were added to the nuclear protein extracts and modification of the DNA/protein complex was evaluated. In addition, antibodies against TCF3 or ER&#x003b1; were used in parallel experiments, without producing any modification of this pattern (Supplementary <xref ref-type="supplementary-material" rid="pone.0005153.s004">Figure S4</xref>). Only in the case of the anti-LEF-1 antibody was a more slowly migrating band observed. The arrow with an asterisk indicates the appearance of a higher molecular weight complex.</p></caption><graphic xlink:href="pone.0005153.g007"/></fig><p>Four members of TCF family have been described (TCF1, LEF-1, TCF3, and TCF4), the first three of which are found in neuronal tissues <xref ref-type="bibr" rid="pone.0005153-Galceran1">&#x0005b;24&#x0005d;</xref>. To determine which of these may participate in the TCF/DNA complex described in our system, we pre-incubated the nuclear extracts with specific antibodies against TCF1, LEF-1 or TCF3, as well as with antibodies against ER&#x003b1; or irrelevant IgGs. The antibody against LEF-1 abolished the formation of the DNA-protein complex while the antibodies against TCF1, TCF3 and ER&#x003b1; did not appreciably modify the DNA-protein complex (<xref ref-type="fig" rid="pone-0005153-g007">Figure 7B</xref> and supplementary <xref ref-type="supplementary-material" rid="pone.0005153.s004">Figure S4</xref>).</p></sec><sec id="s2g"><title>Are the genes regulated by estradiol/&#x003b2;-Catenin/LEF-1 similar to those regulated by Wnt/&#x003b2;-Catenin/TCFs?</title><p>Together, the data obtained so far suggested that estradiol might activate a &#x003b2;-Catenin/LEF-1 complex that is similar to that activated by Wnt in other systems. Thus, to shed further light on this new molecular mechanisms, we took advantage of the fact that the &#x00394;56LEF-1 construct may act as a dominant-negative construct and we generated N2a-m cells stably transfected with &#x00394;56LEF-1 (<xref ref-type="fig" rid="pone-0005153-g008">Figure 8A</xref>). This cell line presented a more differentiated morphology, with bipolar extension of two processes (<xref ref-type="fig" rid="pone-0005153-g008">Figure 8A</xref>).</p><fig id="pone-0005153-g008" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005153.g008</object-id><label>Figure 8</label><caption><title>Generation of a stable N2a-m cell line expressing the &#x00394;56LEF-1 protein.</title><p>N2a-m cells were co-transfected with &#x00394;56LEF-1 or the empty pCDNA3 vector containing the Puromycin resistance gene (for details see <xref ref-type="sec" rid="s4"><italic>Methods</italic></xref>). (A)- N2a-m-&#x00394;56LEF-1 expression was observed by dual immunocytochemistry using an LEF-HMGbox antibody (green) and Phalloidin (red). Note the morphological changes associated with the expression of LEF-1 mutant. (B)- RNA from the different stable N2a-m cell lines was obtained and the RT-PCR products were analyzed in agarose gels. Expression of the &#x00394;56LEF-1 plasmid was tested using oligos specific to the &#x00394;56LEF-1 plasmid, in parallel with specific oligos recognizing endogenous LEF-1 protein (LEF-1-wt) as controls. Note that no significant differences in plasmid expression were observed between cells growing in 10&#x00025; FCS compared to those grown in the absence of FCS. (C)-Protein expression was determined to test for the presence of the mutant LEF-1 protein in N2a-m cells. Nuclear extracts were prepared from control and estradiol treated cells, and little accumulation of &#x003b2;-catenin was detected after exposure to estradiol although the estrogen receptor does enter the nucleus. The LEF-HMG box antibody allows us to differentiate full-length LEF-1 from &#x00394;56 LEF-1 in western blots. Nucleolin levels were used as an internal control. The right insert represents the luciferase activity (RLU) of both stable cell lines. A functional analysis was performed to check the loss of estradiol induction over TOPFlash in these cells, as previously reported for the transient transfection (<xref ref-type="fig" rid="pone-0005153-g006">Figure 6C</xref>). The graph shows the normalized <italic>luciferase</italic> activity from at least three independent experiments. The P value from the Student's t-test was &#x0002a;&#x0002a; (P&#x02264;0.01) when compared with control data.</p></caption><graphic xlink:href="pone.0005153.g008"/></fig><p>As an internal control, we analyzed the presence of the &#x00394;56LEF-1 as well as the endogenous LEF-1. The expression of &#x00394;56LEF-1 in this cell line was not drastically impaired, and it was maintained at an mRNA and protein ratio of at least 1&#x02236;1 when compared with LEF-1, in a cell line <italic>mock</italic>-transfected with the empty pcDNA3.1 vector (<xref ref-type="fig" rid="pone-0005153-g008">Figure 8B and C</xref>). The dominant-negative activity of the LEF-1 mutant was observed when the cell line was transiently transfected with TOPFlash. The expression of <italic>luciferase</italic> was still blocked when the cells were incubated with estradiol, as described previously (<xref ref-type="fig" rid="pone-0005153-g008">Figure 8C</xref>). Even though, estrogen receptor and &#x003b2;-catenin may be detected in the nuclear fraction of these transfected cells (<xref ref-type="fig" rid="pone-0005153-g008">Figure 8C</xref>).</p><p>Subsequently, stably transfected N2a-m cells were utilized to obtain the total RNA, either from <italic>empty</italic> pcDNA3/N2a-m (group <bold>A</bold>) or &#x00394;56LEF-1/N2a-m (group <bold>B</bold>). In both cases, cells were treated with estradiol or Wnt3a for 60 minutes and then total RNA was purified. Gene expression from the two stable cell types (<italic>A and B</italic>) was then analyzed using the Applied Biosystems Mouse Genome Survey Microarray (<italic>Applied Biosystems</italic>).</p><p>Genes were normalized with respect to control untreated cells, and divided in different groups. From these groups, we only consider those with differences when compared group <bold>A</bold> versus group <bold>B</bold>, for each treatment. From these we selected those with a log<sub>2</sub>R higher or lower than <bold>1</bold>, being 102 genes upregulated and 121 genes downregulated by estradiol; and 137 genes upregulated and 166 genes downregulated by Wnt3a. <xref ref-type="table" rid="pone-0005153-t001"><bold>Table 1</bold></xref> described the list of the annotated genes present in the protein bank with the <italic>Ref Seq</italic> and the <italic>Gene Name</italic>. In contrast, the genes modified only after estradiol treatment or only after Wnt3a treatment that presented no significant differences between <bold>A</bold> and <bold>B</bold> were discarded. Initially, for the confirmation of the putative deferential response of both cells (A vs B) we selected two genes presented in both arrays that were modified by Wnt as well as by estradiol (Plasminogen and LEF-1). A final validation was performed using specific antibodies against the selected proteins (<xref ref-type="fig" rid="pone-0005153-g009">Figure 9</xref> and <xref ref-type="fig" rid="pone-0005153-g008">8C</xref>). Thus, plasminogen expression in &#x00394;56LEF-1 cells was 2.5 fold higher, although these initial differences were not considerably augmented by treatment with Wnt or estradiol. Similarly, the endogenous LEF-1 was reduced by the presence of the mutant version of this protein (<xref ref-type="fig" rid="pone-0005153-g008">Figure 8</xref>). In addition we selected some genes, previously reported by other laboratories as Wnt targets , such as TCF's, Cyclin D, Myc, MMP's (for updated, please check, The Wnt Homepage, <italic>at </italic><ext-link ext-link-type="uri" xlink:href="http://www.stanford.edu/~rnusse/pathways/targets.html">http://www.stanford.edu/&#x002dc;rnusse/pathways/targets.html</ext-link>).</p><fig id="pone-0005153-g009" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005153.g009</object-id><label>Figure 9</label><caption><title>Gene expression of cDNA/N2a-m and &#x00394;56LEF-1/N2a-m cells after exposure to estradiol.</title><p>(A)- Gene expression profile in cDNA/N2a-m and &#x00394;56LEF-1/N2a-m stables cell lines. The upper panel reflects the gene induction of some selected genes, in microarray analysis of RNA collected after a 45 min exposure to estradiol or Wnt3a to detect the early response. Data is expressed as log<sub>2</sub>R from cDNA/N2a-m cells, that we denoted as group A, and &#x00394;56LEF-1/N2a-m cells, that we denoted as group B. The effect of the treatment was compared between the two stable cell lines (A vs B) (see &#x0201c;<xref ref-type="table" rid="pone-0005153-t001">Table 1</xref>&#x0201d; for a more complete list of the annotated genes). As seen, in the panel we selected some &#x0201c;putative Wnt-regulated genes&#x0201d;, such as <italic>Tcf3</italic>, <italic>Ccnd1</italic> (cyclin D1), <italic>GSK3b</italic>, <italic>Myc</italic> and <italic>LEF-1</italic>, to give some examples of the results in our arrays. We detected changes at the protein level only in <italic>Plg</italic>, although there were several genes whose expression varied. For example, the levels of plasminogen RNA were much higher in group B than group A (ratio AvsB&#x02265;1), and the expression of LEF-1 was higher in &#x00394;56LEF-1 due to the mutant expression (ratio AvsB&#x02264;&#x02212;1). The western blots below are verifications of these differences at the protein level. Among other proteins that did not change between the groups of cells were GSK3 &#x003b2; or myc (see western blots on the right). MMP-2 was tested although it did not display a change in its RNA levels and there was no difference in the total cell extracts. Interestingly, when conditioned medium was prepared, more pro-active MMP-2 (and less active protein) was seen in &#x00394;56LEF-1 cells. &#x0005b;Gene_Symbol: <italic>Plg</italic> (plasminogen), <italic>Tcf3</italic>, <italic>Ccnd1</italic> (cyclin D1), <italic>GSK3b</italic>, <italic>Myc</italic> and <italic>LEF1</italic>&#x0005d;. (B)- Estradiol induction of N-cadherin and cyclin D2 may be affected by expression of the &#x00394;56LEF-1 protein. Total cell extracts from cDNA/N2a-m cells (group A) and &#x00394;56LEF-1/N2a-m cells (group B) were collected 24 h after estradiol or Wnt3a treatment to analyze several known Wnt or estrogen target genes. As seen in western blots, estradiol upregulated E-cadherin, N-cadherin and cyclin D2 expression in group A cells. N-cadherin and cyclin D2 were also upregulated by Wnt in group A cells. In contrast, E-cadherin expression was not Wnt responsive. The regulatory effects of estradiol on E-cadherin, N-cadherin and cyclin D2 expression were lost when &#x00394;56LEF-1 is expressed, as seen in group B cells. In the case of E-cadherin, the loss of functional LEF-1, which acts as a known gene repressor, implies higher protein levels even without stimulation. In contrast, levels of actin or cyclin D1 remained unchanged.</p></caption><graphic xlink:href="pone.0005153.g009"/></fig><table-wrap id="pone-0005153-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005153.t001</object-id><label>Table 1</label><caption><title>Results of the Microarray analysis of gene transcription.</title></caption><graphic id="pone-0005153-t001-1" xlink:href="pone.0005153.t001"/><table frame="hsides" rules="groups" alternate-form-of="pone-0005153-t001-1"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td colspan="3" align="left" rowspan="1">UPREGULATED:</td></tr><tr><td align="left" rowspan="1" colspan="1">RefSeq_NM</td><td align="left" rowspan="1" colspan="1">est_A vs B</td><td align="left" rowspan="1" colspan="1">Gene_Name</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">NM_007990.1</td><td align="left" rowspan="1" colspan="1">2,739</td><td align="left" rowspan="1" colspan="1">Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV) ubiquitously expressed (fox derived)</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_133198.1</td><td align="left" rowspan="1" colspan="1">2,676</td><td align="left" rowspan="1" colspan="1">liver glycogen phosphorylase</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_130888.1</td><td align="left" rowspan="1" colspan="1">2,457</td><td align="left" rowspan="1" colspan="1">nuclear RNA export factor 7</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_025703.2</td><td align="left" rowspan="1" colspan="1">2,439</td><td align="left" rowspan="1" colspan="1">RIKEN cDNA 3930402F23 gene</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_183271.1</td><td align="left" rowspan="1" colspan="1">2,181</td><td align="left" rowspan="1" colspan="1">RIKEN cDNA 1700049M11 gene</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_008877.2</td><td align="left" rowspan="1" colspan="1">2,039</td><td align="left" rowspan="1" colspan="1"><bold>plasminogen</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">NM_007407.2</td><td align="left" rowspan="1" colspan="1">2,034</td><td align="left" rowspan="1" colspan="1">adenylate cyclase activating polypeptide 1 receptor 1</td></tr><tr><td align="left" rowspan="1" colspan="1">D87975.1</td><td align="left" rowspan="1" colspan="1">1,994</td><td align="left" rowspan="1" colspan="1">serine (or cysteine) proteinase inhibitor, clade F, member 1</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_019703.2</td><td align="left" rowspan="1" colspan="1">1,890</td><td align="left" rowspan="1" colspan="1">phosphofructokinase, platelet</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_010480.4</td><td align="left" rowspan="1" colspan="1">1,847</td><td align="left" rowspan="1" colspan="1">heat shock protein 1, alpha</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_054095.1</td><td align="left" rowspan="1" colspan="1">1,846</td><td align="left" rowspan="1" colspan="1">EF hand calcium binding protein 2</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_013779.1</td><td align="left" rowspan="1" colspan="1">1,701</td><td align="left" rowspan="1" colspan="1">melanoma antigen, family L, 2</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_021389.3</td><td align="left" rowspan="1" colspan="1">1,653</td><td align="left" rowspan="1" colspan="1">SH3-domain kinase binding protein 1</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_009529.1</td><td align="left" rowspan="1" colspan="1">1,509</td><td align="left" rowspan="1" colspan="1">Xlr-related, meiosis regulated</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_133362.1</td><td align="left" rowspan="1" colspan="1">1,491</td><td align="left" rowspan="1" colspan="1">erythroid differentiation regulator 1</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_183294.1</td><td align="left" rowspan="1" colspan="1">1,487</td><td align="left" rowspan="1" colspan="1">cyclin-dependent kinase-like 1 (CDC2-related kinase)</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_007833.1</td><td align="left" rowspan="1" colspan="1">1,462</td><td align="left" rowspan="1" colspan="1">decorin</td></tr><tr><td align="left" rowspan="1" colspan="1">BC053970.1</td><td align="left" rowspan="1" colspan="1">1,337</td><td align="left" rowspan="1" colspan="1">NADH dehydrogenase (ubiquinone) 1, alpha/beta subcomplex, 1</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_008144.3</td><td align="left" rowspan="1" colspan="1">1,335</td><td align="left" rowspan="1" colspan="1">Bernardinelli-Seip congenital lipodystrophy 2 homolog (human)</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_033325.1</td><td align="left" rowspan="1" colspan="1">1,332</td><td align="left" rowspan="1" colspan="1">lysyl oxidase-like 2</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_175027.2</td><td align="left" rowspan="1" colspan="1">1,321</td><td align="left" rowspan="1" colspan="1">cDNA sequence BC022692</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_146034.1</td><td align="left" rowspan="1" colspan="1">1,316</td><td align="left" rowspan="1" colspan="1">meningioma expressed antigen 6 (coiled-coil proline-rich)</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_177752.2</td><td align="left" rowspan="1" colspan="1">1,313</td><td align="left" rowspan="1" colspan="1">hypothetical protein 6820428D13</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_025437.2</td><td align="left" rowspan="1" colspan="1">1,298</td><td align="left" rowspan="1" colspan="1">eukaryotic translation initiation factor 1A, Y-linked</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_019768.2</td><td align="left" rowspan="1" colspan="1">1,291</td><td align="left" rowspan="1" colspan="1">mortality factor 4 like 2</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_008590.1</td><td align="left" rowspan="1" colspan="1">1,251</td><td align="left" rowspan="1" colspan="1">mesoderm specific transcript</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_019647.3</td><td align="left" rowspan="1" colspan="1">1,247</td><td align="left" rowspan="1" colspan="1">ribosomal protein L21</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_031174.2</td><td align="left" rowspan="1" colspan="1">1,246</td><td align="left" rowspan="1" colspan="1">Down syndrome cell adhesion molecule</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_009093.1</td><td align="left" rowspan="1" colspan="1">1,237</td><td align="left" rowspan="1" colspan="1">ribosomal protein S29</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_008200.1</td><td align="left" rowspan="1" colspan="1">1,225</td><td align="left" rowspan="1" colspan="1">histocompatibility 2, D region locus 4</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_008033.2</td><td align="left" rowspan="1" colspan="1">1,222</td><td align="left" rowspan="1" colspan="1">farnesyltransferase, CAAX box, alpha</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_026712.1</td><td align="left" rowspan="1" colspan="1">1,216</td><td align="left" rowspan="1" colspan="1">RIKEN cDNA 0610030H11 gene</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_183203.1</td><td align="left" rowspan="1" colspan="1">1,202</td><td align="left" rowspan="1" colspan="1">hypothetical protein 9130430E04</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_145628.2</td><td align="left" rowspan="1" colspan="1">1,200</td><td align="left" rowspan="1" colspan="1">ubiquitin specific protease 11</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_207204.1</td><td align="left" rowspan="1" colspan="1">1,188</td><td align="left" rowspan="1" colspan="1">RIKEN cDNA 4930519N13 gene</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_025695.2</td><td align="left" rowspan="1" colspan="1">1,178</td><td align="left" rowspan="1" colspan="1">SMC6 structural maintenance of chromosomes 6-like 1 (yeast)</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_008183.2</td><td align="left" rowspan="1" colspan="1">1,177</td><td align="left" rowspan="1" colspan="1">glutathione S-transferase, mu 2</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_145526.1</td><td align="left" rowspan="1" colspan="1">1,173</td><td align="left" rowspan="1" colspan="1">purinergic receptor P2X, ligand-gated ion channel, 3</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_012035.1</td><td align="left" rowspan="1" colspan="1">1,136</td><td align="left" rowspan="1" colspan="1">transient receptor potential cation channel, subfamily C, member 7</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_010206.1</td><td align="left" rowspan="1" colspan="1">1,135</td><td align="left" rowspan="1" colspan="1">fibroblast growth factor receptor 1</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_146035.1</td><td align="left" rowspan="1" colspan="1">1,122</td><td align="left" rowspan="1" colspan="1">mannoside acetylglucosaminyltransferase 2</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_175930.2</td><td align="left" rowspan="1" colspan="1">1,118</td><td align="left" rowspan="1" colspan="1">Rap guanine nucleotide exchange factor (GEF) 5</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_013819.1</td><td align="left" rowspan="1" colspan="1">1,111</td><td align="left" rowspan="1" colspan="1">histocompatibility 2, M region locus 3</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_008666.1</td><td align="left" rowspan="1" colspan="1">1,094</td><td align="left" rowspan="1" colspan="1">myelin transcription factor 1-like</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_029823.1</td><td align="left" rowspan="1" colspan="1">1,092</td><td align="left" rowspan="1" colspan="1">RIKEN cDNA 6530401D17 gene</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_172758.1</td><td align="left" rowspan="1" colspan="1">1,090</td><td align="left" rowspan="1" colspan="1">cDNA sequence BC031853</td></tr><tr><td align="left" rowspan="1" colspan="1">AK040457.1</td><td align="left" rowspan="1" colspan="1">1,085</td><td align="left" rowspan="1" colspan="1">interleukin 27 receptor, alpha</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_194355.1</td><td align="left" rowspan="1" colspan="1">1,079</td><td align="left" rowspan="1" colspan="1">spire homolog 1 (Drosophila)</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_007881.4</td><td align="left" rowspan="1" colspan="1">1,072</td><td align="left" rowspan="1" colspan="1">dentatorubral pallidoluysian atrophy</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_025522.1</td><td align="left" rowspan="1" colspan="1">1,064</td><td align="left" rowspan="1" colspan="1">dehydrogenase/reductase (SDR family) member 7</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_008549.1</td><td align="left" rowspan="1" colspan="1">1,063</td><td align="left" rowspan="1" colspan="1">mannosidase 2, alpha 1</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_010545.2</td><td align="left" rowspan="1" colspan="1">1,058</td><td align="left" rowspan="1" colspan="1">Ia-associated invariant chain</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_008810.2</td><td align="left" rowspan="1" colspan="1">1,058</td><td align="left" rowspan="1" colspan="1">pyruvate dehydrogenase E1 alpha 1</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_175007.1</td><td align="left" rowspan="1" colspan="1">1,044</td><td align="left" rowspan="1" colspan="1">amphiphysin</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_028270.2</td><td align="left" rowspan="1" colspan="1">1,029</td><td align="left" rowspan="1" colspan="1">aldehyde dehydrogenase 1 family, member B1</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_008737.1</td><td align="left" rowspan="1" colspan="1">1,024</td><td align="left" rowspan="1" colspan="1">neuropilin</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_008666.1</td><td align="left" rowspan="1" colspan="1">1,023</td><td align="left" rowspan="1" colspan="1">myelin transcription factor 1-like</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_025932.1</td><td align="left" rowspan="1" colspan="1">1,016</td><td align="left" rowspan="1" colspan="1">synapse associated protein 1</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_010195.1</td><td align="left" rowspan="1" colspan="1">1,006</td><td align="left" rowspan="1" colspan="1">G protein-coupled receptor 49</td></tr></tbody></table><table frame="hsides" rules="groups" alternate-form-of="pone-0005153-t001-1"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td colspan="3" align="left" rowspan="1">DOWNREGULATED:</td></tr><tr><td align="left" rowspan="1" colspan="1">RefSeq_NM</td><td align="left" rowspan="1" colspan="1">est_AvsB</td><td align="left" rowspan="1" colspan="1">Gene_Name</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">NM_019932.1</td><td align="left" rowspan="1" colspan="1">&#x02212;3,893</td><td align="left" rowspan="1" colspan="1">chemokine (C-X-C motif) ligand 4</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_010703.2</td><td align="left" rowspan="1" colspan="1">&#x02212;2,642</td><td align="left" rowspan="1" colspan="1"><bold>lymphoid enhancer binding factor 1</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">NM_013492.1</td><td align="left" rowspan="1" colspan="1">&#x02212;2,293</td><td align="left" rowspan="1" colspan="1">clusterin</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_011702.1</td><td align="left" rowspan="1" colspan="1">&#x02212;2,053</td><td align="left" rowspan="1" colspan="1">vasoactive intestinal polypeptide</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_010685.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,992</td><td align="left" rowspan="1" colspan="1">lysosomal membrane glycoprotein 2</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_011333.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,986</td><td align="left" rowspan="1" colspan="1">chemokine (C-C motif) ligand 2</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_010658.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,809</td><td align="left" rowspan="1" colspan="1">v-maf musculoaponeurotic fibrosarcoma oncogene family, protein B (avian)</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_010515.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,705</td><td align="left" rowspan="1" colspan="1">insulin-like growth factor 2 receptor</td></tr><tr><td align="left" rowspan="1" colspan="1">AK033214.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,677</td><td align="left" rowspan="1" colspan="1">G elongation factor</td></tr><tr><td align="left" rowspan="1" colspan="1">BC053489.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,557</td><td align="left" rowspan="1" colspan="1">insulin-like growth factor 2</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_023422.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,438</td><td align="left" rowspan="1" colspan="1">histone 1, H2bc</td></tr><tr><td align="left" rowspan="1" colspan="1">AK027922.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,427</td><td align="left" rowspan="1" colspan="1">glutathione S-transferase omega 1</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_177708.3</td><td align="left" rowspan="1" colspan="1">&#x02212;1,420</td><td align="left" rowspan="1" colspan="1">reticulon 4 receptor-like 1</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_175395.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,418</td><td align="left" rowspan="1" colspan="1">RIKEN cDNA 1700001A24 gene;RIKEN cDNA 6330578E17 gene</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_053273.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,410</td><td align="left" rowspan="1" colspan="1">tweety homolog 2 (Drosophila)</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_009344.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,395</td><td align="left" rowspan="1" colspan="1">pleckstrin homology-like domain, family A, member 1</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_011844.3</td><td align="left" rowspan="1" colspan="1">&#x02212;1,349</td><td align="left" rowspan="1" colspan="1">monoglyceride lipase</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_009776.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,346</td><td align="left" rowspan="1" colspan="1">serine (or cysteine) proteinase inhibitor, clade G, member 1</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_021274.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,339</td><td align="left" rowspan="1" colspan="1">chemokine (C-X-C motif) ligand 10</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_021897.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,337</td><td align="left" rowspan="1" colspan="1">transformation related protein 53 inducible nuclear protein 1</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_138683.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,303</td><td align="left" rowspan="1" colspan="1">thrombospondin type 1 domain containing gene</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_010789.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,292</td><td align="left" rowspan="1" colspan="1">myeloid ecotropic viral integration site 1</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_016867.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,291</td><td align="left" rowspan="1" colspan="1">semaF cytoplasmic domain associated protein 2</td></tr><tr><td align="left" rowspan="1" colspan="1">BC058269.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,290</td><td align="left" rowspan="1" colspan="1">RAR-related orphan receptor beta</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_007635.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,279</td><td align="left" rowspan="1" colspan="1">cyclin G2</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_015818.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,275</td><td align="left" rowspan="1" colspan="1">heparan sulfate 6-O-sulfotransferase 1</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_026416.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,261</td><td align="left" rowspan="1" colspan="1">S100 calcium binding protein A16</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_145825.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,260</td><td align="left" rowspan="1" colspan="1">centrin 4</td></tr><tr><td align="left" rowspan="1" colspan="1">AK035160.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,252</td><td align="left" rowspan="1" colspan="1">heart and neural crest derivatives expressed transcript 2</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_028535.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,251</td><td align="left" rowspan="1" colspan="1">RIKEN cDNA 1700049E17 gene</td></tr><tr><td align="left" rowspan="1" colspan="1">AK031672.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,246</td><td align="left" rowspan="1" colspan="1">DNA segment, Chr 11, ERATO Doi 498, expressed</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_178405.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,233</td><td align="left" rowspan="1" colspan="1">ATPase, Na&#x0002b;/K&#x0002b; transporting, alpha 2 polypeptide</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_172854.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,213</td><td align="left" rowspan="1" colspan="1">RIKEN cDNA 4932431K08 gene</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_009242.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,180</td><td align="left" rowspan="1" colspan="1">secreted acidic cysteine rich glycoprotein</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_021537.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,172</td><td align="left" rowspan="1" colspan="1">serine/threonine kinase 25 (yeast)</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_008250.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,167</td><td align="left" rowspan="1" colspan="1">H2.0-like homeo box gene</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_008538.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,167</td><td align="left" rowspan="1" colspan="1">myristoylated alanine rich protein kinase C substrate</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_026793.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,166</td><td align="left" rowspan="1" colspan="1">myc target 1</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_011353.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,163</td><td align="left" rowspan="1" colspan="1">small EDRK-rich factor 1</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_026358.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,160</td><td align="left" rowspan="1" colspan="1">RIKEN cDNA 4930583H14 gene</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_009726.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,158</td><td align="left" rowspan="1" colspan="1">ATPase, Cu&#x0002b;&#x0002b; transporting, alpha polypeptide</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_194268.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,155</td><td align="left" rowspan="1" colspan="1">one cut domain, family member 2</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_011295.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,142</td><td align="left" rowspan="1" colspan="1">ribosomal protein S12</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_175103.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,135</td><td align="left" rowspan="1" colspan="1">RIKEN cDNA 1110025L05 gene</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_025836.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,130</td><td align="left" rowspan="1" colspan="1">mannose-6-phosphate receptor binding protein 1</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_025692.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,127</td><td align="left" rowspan="1" colspan="1">ubiquitin-activating enzyme E1-domain containing 1</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_025394.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,126</td><td align="left" rowspan="1" colspan="1">translocase of outer mitochondrial membrane 7 homolog (yeast)</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_028279.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,125</td><td align="left" rowspan="1" colspan="1">N-acetylated alpha-linked acidic dipeptidase 2</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_133780.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,125</td><td align="left" rowspan="1" colspan="1">translocated promoter region</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_013660.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,120</td><td align="left" rowspan="1" colspan="1">sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4D</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_013692.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,120</td><td align="left" rowspan="1" colspan="1">TGFB inducible early growth response 1</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_010357.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,119</td><td align="left" rowspan="1" colspan="1">glutathione S-transferase, alpha 4</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_018865.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,108</td><td align="left" rowspan="1" colspan="1">WNT1 inducible signaling pathway protein 1</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_010317.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,107</td><td align="left" rowspan="1" colspan="1">guanine nucleotide binding protein (G protein), gamma 4 subunit</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_173788.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,101</td><td align="left" rowspan="1" colspan="1">natriuretic peptide receptor 2</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_175238.4</td><td align="left" rowspan="1" colspan="1">&#x02212;1,089</td><td align="left" rowspan="1" colspan="1">DNA segment, Chr 2, ERATO Doi 145, expressed</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_011313.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,088</td><td align="left" rowspan="1" colspan="1">S100 calcium binding protein A6 (calcyclin)</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_025735.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,080</td><td align="left" rowspan="1" colspan="1">microtubule-associated protein 1 light chain 3 alpha</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_178751.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,080</td><td align="left" rowspan="1" colspan="1">RIKEN cDNA A730041O15 gene</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_030037.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,078</td><td align="left" rowspan="1" colspan="1">motile sperm domain containing 3</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_017367.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,078</td><td align="left" rowspan="1" colspan="1">cyclin I</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_133218.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,077</td><td align="left" rowspan="1" colspan="1">glucocorticoid induced gene 1</td></tr><tr><td align="left" rowspan="1" colspan="1">AK010069.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,075</td><td align="left" rowspan="1" colspan="1">DNA segment, Chr 7, Wayne State University 87, expressed</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_026033.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,074</td><td align="left" rowspan="1" colspan="1">ocular development associated gene</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_021398.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,070</td><td align="left" rowspan="1" colspan="1">solute carrier family 43, member 3</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_174988.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,063</td><td align="left" rowspan="1" colspan="1">cadherin 22</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_026111.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,043</td><td align="left" rowspan="1" colspan="1">RIKEN cDNA 1810019P04 gene</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_012057.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,042</td><td align="left" rowspan="1" colspan="1">interferon regulatory factor 5</td></tr><tr><td align="left" rowspan="1" colspan="1">AK076923.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,042</td><td align="left" rowspan="1" colspan="1">protein phosphatase 1B, magnesium dependent, beta isoform</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_133859.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,040</td><td align="left" rowspan="1" colspan="1">olfactomedin-like 3</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_026565.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,038</td><td align="left" rowspan="1" colspan="1">RIKEN cDNA 9430083G14 gene</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_133942.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,037</td><td align="left" rowspan="1" colspan="1">expressed sequence AA960558</td></tr><tr><td align="left" rowspan="1" colspan="1">AK003039.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,030</td><td align="left" rowspan="1" colspan="1">glycolipid transfer protein</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_008967.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,022</td><td align="left" rowspan="1" colspan="1">prostaglandin I receptor (IP)</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_023649.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,020</td><td align="left" rowspan="1" colspan="1">Usher syndrome 1C homolog (human)</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_025946.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,013</td><td align="left" rowspan="1" colspan="1">RIKEN cDNA 2010100O12 gene</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_009113.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,010</td><td align="left" rowspan="1" colspan="1">S100 calcium binding protein A13</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_027285.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,009</td><td align="left" rowspan="1" colspan="1">RIKEN cDNA 1700029I01 gene</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_172296.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,009</td><td align="left" rowspan="1" colspan="1">doublesex and mab-3 related transcription factor like family A2</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_009814.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,007</td><td align="left" rowspan="1" colspan="1">calsequestrin 2</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_013765.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,005</td><td align="left" rowspan="1" colspan="1">ribosomal protein S26</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_011952.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,003</td><td align="left" rowspan="1" colspan="1">mitogen activated protein kinase 3</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_010831.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,001</td><td align="left" rowspan="1" colspan="1">SNF1-like kinase</td></tr></tbody></table><table frame="hsides" rules="groups" alternate-form-of="pone-0005153-t001-1"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td colspan="4" align="left" rowspan="1">UPREGULATED:</td></tr><tr><td align="left" rowspan="1" colspan="1">RefSeq_NM</td><td align="left" rowspan="1" colspan="1">Wnt_AvsB</td><td align="left" rowspan="1" colspan="1">Gene_Symbol</td><td align="left" rowspan="1" colspan="1">Gene_Name</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">NM_007990.1</td><td align="left" rowspan="1" colspan="1">3,603</td><td align="left" rowspan="1" colspan="1">Fau</td><td align="left" rowspan="1" colspan="1">Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV) ubiquitously expressed (fox derived)</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_133198.1</td><td align="left" rowspan="1" colspan="1">2,620</td><td align="left" rowspan="1" colspan="1">Pygl</td><td align="left" rowspan="1" colspan="1">liver glycogen phosphorylase</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_019703.2</td><td align="left" rowspan="1" colspan="1">2,343</td><td align="left" rowspan="1" colspan="1">Pfkp</td><td align="left" rowspan="1" colspan="1">phosphofructokinase, platelet</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_007407.2</td><td align="left" rowspan="1" colspan="1">2,294</td><td align="left" rowspan="1" colspan="1">Adcyap1r1</td><td align="left" rowspan="1" colspan="1">adenylate cyclase activating polypeptide 1 receptor 1</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_025703.2</td><td align="left" rowspan="1" colspan="1">2,270</td><td align="left" rowspan="1" colspan="1">3930402F23Rik</td><td align="left" rowspan="1" colspan="1">RIKEN cDNA 3930402F23 gene</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_183271.1</td><td align="left" rowspan="1" colspan="1">2,215</td><td align="left" rowspan="1" colspan="1">1700049M11Rik</td><td align="left" rowspan="1" colspan="1">RIKEN cDNA 1700049M11 gene</td></tr><tr><td align="left" rowspan="1" colspan="1">BC053970.1</td><td align="left" rowspan="1" colspan="1">2,198</td><td align="left" rowspan="1" colspan="1">Ndufab1</td><td align="left" rowspan="1" colspan="1">NADH dehydrogenase (ubiquinone) 1, alpha/beta subcomplex, 1</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_130888.1</td><td align="left" rowspan="1" colspan="1">2,106</td><td align="left" rowspan="1" colspan="1">Nxf7</td><td align="left" rowspan="1" colspan="1">nuclear RNA export factor 7</td></tr><tr><td align="left" rowspan="1" colspan="1">D87975.1</td><td align="left" rowspan="1" colspan="1">2,052</td><td align="left" rowspan="1" colspan="1">Serpinf1</td><td align="left" rowspan="1" colspan="1">serine (or cysteine) proteinase inhibitor, clade F, member 1</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_021389.3</td><td align="left" rowspan="1" colspan="1">1,966</td><td align="left" rowspan="1" colspan="1">Sh3kbp1</td><td align="left" rowspan="1" colspan="1">SH3-domain kinase binding protein 1</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_054095.1</td><td align="left" rowspan="1" colspan="1">1,910</td><td align="left" rowspan="1" colspan="1">Efcbp2</td><td align="left" rowspan="1" colspan="1">EF hand calcium binding protein 2</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_133362.1</td><td align="left" rowspan="1" colspan="1">1,797</td><td align="left" rowspan="1" colspan="1">Erdr1</td><td align="left" rowspan="1" colspan="1">erythroid differentiation regulator 1</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_177752.2</td><td align="left" rowspan="1" colspan="1">1,682</td><td align="left" rowspan="1" colspan="1">6820428D13</td><td align="left" rowspan="1" colspan="1">hypothetical protein 6820428D13</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_172960.1</td><td align="left" rowspan="1" colspan="1">1,608</td><td align="left" rowspan="1" colspan="1">Adck5</td><td align="left" rowspan="1" colspan="1">aarF domain containing kinase 5</td></tr><tr><td align="left" rowspan="1" colspan="1">AK040457.1</td><td align="left" rowspan="1" colspan="1">1,501</td><td align="left" rowspan="1" colspan="1">Il27ra</td><td align="left" rowspan="1" colspan="1">interleukin 27 receptor, alpha</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_008595.1</td><td align="left" rowspan="1" colspan="1">1,446</td><td align="left" rowspan="1" colspan="1">Mfng</td><td align="left" rowspan="1" colspan="1">manic fringe homolog (Drosophila)</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_033325.1</td><td align="left" rowspan="1" colspan="1">1,445</td><td align="left" rowspan="1" colspan="1">Loxl2</td><td align="left" rowspan="1" colspan="1">lysyl oxidase-like 2</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_145526.1</td><td align="left" rowspan="1" colspan="1">1,425</td><td align="left" rowspan="1" colspan="1">P2rx3</td><td align="left" rowspan="1" colspan="1">purinergic receptor P2X, ligand-gated ion channel, 3</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_008183.2</td><td align="left" rowspan="1" colspan="1">1,419</td><td align="left" rowspan="1" colspan="1">Gstm2</td><td align="left" rowspan="1" colspan="1">glutathione S-transferase, mu 2</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_025695.2</td><td align="left" rowspan="1" colspan="1">1,414</td><td align="left" rowspan="1" colspan="1">Smc6l1</td><td align="left" rowspan="1" colspan="1">SMC6 structural maintenance of chromosomes 6-like 1 (yeast)</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_009369.1</td><td align="left" rowspan="1" colspan="1">1,414</td><td align="left" rowspan="1" colspan="1">Tgfbi</td><td align="left" rowspan="1" colspan="1">transforming growth factor, beta induced</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_025522.1</td><td align="left" rowspan="1" colspan="1">1,410</td><td align="left" rowspan="1" colspan="1">Dhrs7</td><td align="left" rowspan="1" colspan="1">dehydrogenase/reductase (SDR family) member 7</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_007997.1</td><td align="left" rowspan="1" colspan="1">1,399</td><td align="left" rowspan="1" colspan="1">Fdxr</td><td align="left" rowspan="1" colspan="1">ferredoxin reductase</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_207204.1</td><td align="left" rowspan="1" colspan="1">1,382</td><td align="left" rowspan="1" colspan="1">4930519N13Rik</td><td align="left" rowspan="1" colspan="1">RIKEN cDNA 4930519N13 gene</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_007833.1</td><td align="left" rowspan="1" colspan="1">1,360</td><td align="left" rowspan="1" colspan="1">Dcn</td><td align="left" rowspan="1" colspan="1">decorin</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_008877.2</td><td align="left" rowspan="1" colspan="1">1,342</td><td align="left" rowspan="1" colspan="1">Plg</td><td align="left" rowspan="1" colspan="1"><bold>plasminogen</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">NM_019966.1</td><td align="left" rowspan="1" colspan="1">1,331</td><td align="left" rowspan="1" colspan="1">Mlycd</td><td align="left" rowspan="1" colspan="1">malonyl-CoA decarboxylase</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_175027.2</td><td align="left" rowspan="1" colspan="1">1,316</td><td align="left" rowspan="1" colspan="1">BC022692</td><td align="left" rowspan="1" colspan="1">cDNA sequence BC022692</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_080553.1</td><td align="left" rowspan="1" colspan="1">1,309</td><td align="left" rowspan="1" colspan="1">Itpr3</td><td align="left" rowspan="1" colspan="1">inositol 1,4,5-triphosphate receptor 3</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_010480.4</td><td align="left" rowspan="1" colspan="1">1,308</td><td align="left" rowspan="1" colspan="1">Hspca</td><td align="left" rowspan="1" colspan="1">heat shock protein 1, alpha</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_029823.1</td><td align="left" rowspan="1" colspan="1">1,273</td><td align="left" rowspan="1" colspan="1">6530401D17Rik</td><td align="left" rowspan="1" colspan="1">RIKEN cDNA 6530401D17 gene</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_008144.3</td><td align="left" rowspan="1" colspan="1">1,273</td><td align="left" rowspan="1" colspan="1">Bscl2</td><td align="left" rowspan="1" colspan="1">Bernardinelli-Seip congenital lipodystrophy 2 homolog (human)</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_198031.1</td><td align="left" rowspan="1" colspan="1">1,266</td><td align="left" rowspan="1" colspan="1">Tubgcp3</td><td align="left" rowspan="1" colspan="1">tubulin, gamma complex associated protein 3</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_008810.2</td><td align="left" rowspan="1" colspan="1">1,249</td><td align="left" rowspan="1" colspan="1">Pdha1</td><td align="left" rowspan="1" colspan="1">pyruvate dehydrogenase E1 alpha 1</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_008666.1</td><td align="left" rowspan="1" colspan="1">1,246</td><td align="left" rowspan="1" colspan="1">Myt1l</td><td align="left" rowspan="1" colspan="1">myelin transcription factor 1-like</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_173427.1</td><td align="left" rowspan="1" colspan="1">1,240</td><td align="left" rowspan="1" colspan="1">B230308G19Rik</td><td align="left" rowspan="1" colspan="1">RIKEN cDNA B230308G19 gene</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_178794.2</td><td align="left" rowspan="1" colspan="1">1,234</td><td align="left" rowspan="1" colspan="1">U2af1-rs2</td><td align="left" rowspan="1" colspan="1">U2 small nuclear ribonucleoprotein auxiliary factor (U2AF) 1, related sequence 2</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_146034.1</td><td align="left" rowspan="1" colspan="1">1,234</td><td align="left" rowspan="1" colspan="1">Mgea6</td><td align="left" rowspan="1" colspan="1">meningioma expressed antigen 6 (coiled-coil proline-rich)</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_019552.1</td><td align="left" rowspan="1" colspan="1">1,229</td><td align="left" rowspan="1" colspan="1">Abcb10</td><td align="left" rowspan="1" colspan="1">ATP-binding cassette, sub-family B (MDR/TAP), member 10</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_178915.2</td><td align="left" rowspan="1" colspan="1">1,221</td><td align="left" rowspan="1" colspan="1">AI839735</td><td align="left" rowspan="1" colspan="1">expressed sequence AI839735</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_008243.2</td><td align="left" rowspan="1" colspan="1">1,215</td><td align="left" rowspan="1" colspan="1">Mst1</td><td align="left" rowspan="1" colspan="1">macrophage stimulating 1 (hepatocyte growth factor-like)</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_145482.1</td><td align="left" rowspan="1" colspan="1">1,175</td><td align="left" rowspan="1" colspan="1">ORF21</td><td align="left" rowspan="1" colspan="1">open reading frame 21</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_025936.1</td><td align="left" rowspan="1" colspan="1">1,173</td><td align="left" rowspan="1" colspan="1">Rars</td><td align="left" rowspan="1" colspan="1">arginyl-tRNA synthetase</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_028262.1</td><td align="left" rowspan="1" colspan="1">1,168</td><td align="left" rowspan="1" colspan="1">D12Ertd771e</td><td align="left" rowspan="1" colspan="1">DNA segment, Chr 12, ERATO Doi 771, expressed</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_031174.2</td><td align="left" rowspan="1" colspan="1">1,164</td><td align="left" rowspan="1" colspan="1">Dscam</td><td align="left" rowspan="1" colspan="1">Down syndrome cell adhesion molecule</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_023304.1</td><td align="left" rowspan="1" colspan="1">1,149</td><td align="left" rowspan="1" colspan="1">Fgf22</td><td align="left" rowspan="1" colspan="1">fibroblast growth factor 22</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_025932.1</td><td align="left" rowspan="1" colspan="1">1,139</td><td align="left" rowspan="1" colspan="1">Syap1</td><td align="left" rowspan="1" colspan="1">synapse associated protein 1</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_013778.1</td><td align="left" rowspan="1" colspan="1">1,130</td><td align="left" rowspan="1" colspan="1">Akr1c13;Akr1c12</td><td align="left" rowspan="1" colspan="1">aldo-keto reductase family 1, member C13;aldo-keto reductase family 1, member C12</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_013819.1</td><td align="left" rowspan="1" colspan="1">1,129</td><td align="left" rowspan="1" colspan="1">H2-M3</td><td align="left" rowspan="1" colspan="1">histocompatibility 2, M region locus 3</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_007407.2</td><td align="left" rowspan="1" colspan="1">1,126</td><td align="left" rowspan="1" colspan="1">Adcyap1r1</td><td align="left" rowspan="1" colspan="1">adenylate cyclase activating polypeptide 1 receptor 1</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_021273.2</td><td align="left" rowspan="1" colspan="1">1,122</td><td align="left" rowspan="1" colspan="1">Ckb</td><td align="left" rowspan="1" colspan="1">creatine kinase, brain</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_008033.2</td><td align="left" rowspan="1" colspan="1">1,119</td><td align="left" rowspan="1" colspan="1">Fnta</td><td align="left" rowspan="1" colspan="1">farnesyltransferase, CAAX box, alpha</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_009529.1</td><td align="left" rowspan="1" colspan="1">1,115</td><td align="left" rowspan="1" colspan="1">Xmr</td><td align="left" rowspan="1" colspan="1">Xlr-related, meiosis regulated</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_207269.1</td><td align="left" rowspan="1" colspan="1">1,111</td><td align="left" rowspan="1" colspan="1">D330050I23Rik</td><td align="left" rowspan="1" colspan="1">RIKEN cDNA D330050I23 gene</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_010752.1</td><td align="left" rowspan="1" colspan="1">1,108</td><td align="left" rowspan="1" colspan="1">Mad1l1</td><td align="left" rowspan="1" colspan="1">mitotic arrest deficient 1-like 1</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_028089.1</td><td align="left" rowspan="1" colspan="1">1,091</td><td align="left" rowspan="1" colspan="1">Cyp2c55</td><td align="left" rowspan="1" colspan="1">cytochrome P450, family 2, subfamily c, polypeptide 55</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_133224.1</td><td align="left" rowspan="1" colspan="1">1,090</td><td align="left" rowspan="1" colspan="1">Atp13a</td><td align="left" rowspan="1" colspan="1">ATPase type 13A</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_025656.1</td><td align="left" rowspan="1" colspan="1">1,089</td><td align="left" rowspan="1" colspan="1">Sip1</td><td align="left" rowspan="1" colspan="1">survivor of motor neuron protein interacting protein 1</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_028002.1</td><td align="left" rowspan="1" colspan="1">1,088</td><td align="left" rowspan="1" colspan="1">2310069P03Rik</td><td align="left" rowspan="1" colspan="1">RIKEN cDNA 2310069P03 gene</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_010724.1</td><td align="left" rowspan="1" colspan="1">1,086</td><td align="left" rowspan="1" colspan="1">Psmb8</td><td align="left" rowspan="1" colspan="1">proteosome (prosome, macropain) subunit, beta type 8</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_028131.1</td><td align="left" rowspan="1" colspan="1">1,081</td><td align="left" rowspan="1" colspan="1">2610510J17Rik</td><td align="left" rowspan="1" colspan="1">RIKEN cDNA 2610510J17 gene</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_009239.1</td><td align="left" rowspan="1" colspan="1">1,080</td><td align="left" rowspan="1" colspan="1">Sp4</td><td align="left" rowspan="1" colspan="1">trans-acting transcription factor 4</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_025437.2</td><td align="left" rowspan="1" colspan="1">1,077</td><td align="left" rowspan="1" colspan="1">Eif1ay</td><td align="left" rowspan="1" colspan="1">eukaryotic translation initiation factor 1A, Y-linked</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_183294.1</td><td align="left" rowspan="1" colspan="1">1,072</td><td align="left" rowspan="1" colspan="1">Cdkl1</td><td align="left" rowspan="1" colspan="1">cyclin-dependent kinase-like 1 (CDC2-related kinase)</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_013779.1</td><td align="left" rowspan="1" colspan="1">1,070</td><td align="left" rowspan="1" colspan="1">Magel2</td><td align="left" rowspan="1" colspan="1">melanoma antigen, family L, 2</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_021556.2</td><td align="left" rowspan="1" colspan="1">1,063</td><td align="left" rowspan="1" colspan="1">Mrps30</td><td align="left" rowspan="1" colspan="1">mitochondrial ribosomal protein S30</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_207210.1</td><td align="left" rowspan="1" colspan="1">1,059</td><td align="left" rowspan="1" colspan="1">Dyrk4</td><td align="left" rowspan="1" colspan="1">dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 4</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_146035.1</td><td align="left" rowspan="1" colspan="1">1,057</td><td align="left" rowspan="1" colspan="1">Mgat2</td><td align="left" rowspan="1" colspan="1">mannoside acetylglucosaminyltransferase 2</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_144844.1</td><td align="left" rowspan="1" colspan="1">1,049</td><td align="left" rowspan="1" colspan="1">Pcca</td><td align="left" rowspan="1" colspan="1">propionyl-Coenzyme A carboxylase, alpha polypeptide</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_178389.2</td><td align="left" rowspan="1" colspan="1">1,045</td><td align="left" rowspan="1" colspan="1">Gale</td><td align="left" rowspan="1" colspan="1">galactose-4-epimerase, UDP</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_012035.1</td><td align="left" rowspan="1" colspan="1">1,041</td><td align="left" rowspan="1" colspan="1">Trpc7</td><td align="left" rowspan="1" colspan="1">transient receptor potential cation channel, subfamily C, member 7</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_176953.2</td><td align="left" rowspan="1" colspan="1">1,034</td><td align="left" rowspan="1" colspan="1">Lig4</td><td align="left" rowspan="1" colspan="1">ligase IV, DNA, ATP-dependent</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_008183.2</td><td align="left" rowspan="1" colspan="1">1,033</td><td align="left" rowspan="1" colspan="1">Gstm2</td><td align="left" rowspan="1" colspan="1">glutathione S-transferase, mu 2</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_178242.2</td><td align="left" rowspan="1" colspan="1">1,032</td><td align="left" rowspan="1" colspan="1">Zfp469</td><td align="left" rowspan="1" colspan="1">zinc finger protein 469</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_009933.1</td><td align="left" rowspan="1" colspan="1">1,030</td><td align="left" rowspan="1" colspan="1">Col6a1</td><td align="left" rowspan="1" colspan="1">procollagen, type VI, alpha 1</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_010068.1</td><td align="left" rowspan="1" colspan="1">1,030</td><td align="left" rowspan="1" colspan="1">Dnmt3b</td><td align="left" rowspan="1" colspan="1">DNA methyltransferase 3B</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_028270.2</td><td align="left" rowspan="1" colspan="1">1,027</td><td align="left" rowspan="1" colspan="1">Aldh1b1</td><td align="left" rowspan="1" colspan="1">aldehyde dehydrogenase 1 family, member B1</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_172783.1</td><td align="left" rowspan="1" colspan="1">1,022</td><td align="left" rowspan="1" colspan="1">Phka2</td><td align="left" rowspan="1" colspan="1">phosphorylase kinase alpha 2</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_008590.1</td><td align="left" rowspan="1" colspan="1">1,020</td><td align="left" rowspan="1" colspan="1">Mest</td><td align="left" rowspan="1" colspan="1">mesoderm specific transcript</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_013761.2</td><td align="left" rowspan="1" colspan="1">1,017</td><td align="left" rowspan="1" colspan="1">Srr</td><td align="left" rowspan="1" colspan="1">serine racemase</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_029541.1</td><td align="left" rowspan="1" colspan="1">1,017</td><td align="left" rowspan="1" colspan="1">6530401D17Rik</td><td align="left" rowspan="1" colspan="1">RIKEN cDNA 6530401D17 gene</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_025486.1</td><td align="left" rowspan="1" colspan="1">1,012</td><td align="left" rowspan="1" colspan="1">1700006C06Rik</td><td align="left" rowspan="1" colspan="1">RIKEN cDNA 1700006C06 gene</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_130864.2</td><td align="left" rowspan="1" colspan="1">1,012</td><td align="left" rowspan="1" colspan="1">Acaa1</td><td align="left" rowspan="1" colspan="1">acetyl-Coenzyme A acyltransferase 1</td></tr></tbody></table><table frame="hsides" rules="groups" alternate-form-of="pone-0005153-t001-1"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td colspan="4" align="left" rowspan="1">DOWNREGULATED:</td></tr><tr><td align="left" rowspan="1" colspan="1">RefSeq_NM</td><td align="left" rowspan="1" colspan="1">Wnt_AvsB</td><td align="left" rowspan="1" colspan="1">Gene_Symbol</td><td align="left" rowspan="1" colspan="1">Gene_Name</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">NM_019932.1</td><td align="left" rowspan="1" colspan="1">&#x02212;3,616</td><td align="left" rowspan="1" colspan="1">Cxcl4</td><td align="left" rowspan="1" colspan="1">chemokine (C-X-C motif) ligand 4</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_010703.2</td><td align="left" rowspan="1" colspan="1">&#x02212;3,395</td><td align="left" rowspan="1" colspan="1">Lef1</td><td align="left" rowspan="1" colspan="1"><bold>lymphoid enhancer binding factor 1</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">NM_011702.1</td><td align="left" rowspan="1" colspan="1">&#x02212;2,102</td><td align="left" rowspan="1" colspan="1">Vip</td><td align="left" rowspan="1" colspan="1">vasoactive intestinal polypeptide</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_010685.2</td><td align="left" rowspan="1" colspan="1">&#x02212;2,085</td><td align="left" rowspan="1" colspan="1">Lamp2</td><td align="left" rowspan="1" colspan="1">lysosomal membrane glycoprotein 2</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_011333.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,843</td><td align="left" rowspan="1" colspan="1">Ccl2</td><td align="left" rowspan="1" colspan="1">chemokine (C-C motif) ligand 2</td></tr><tr><td align="left" rowspan="1" colspan="1">AK027922.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,770</td><td align="left" rowspan="1" colspan="1">Gsto1</td><td align="left" rowspan="1" colspan="1">glutathione S-transferase omega 1</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_010515.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,748</td><td align="left" rowspan="1" colspan="1">Igf2r</td><td align="left" rowspan="1" colspan="1">insulin-like growth factor 2 receptor</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_007635.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,679</td><td align="left" rowspan="1" colspan="1">Ccng2</td><td align="left" rowspan="1" colspan="1">cyclin G2</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_013492.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,634</td><td align="left" rowspan="1" colspan="1">Clu</td><td align="left" rowspan="1" colspan="1">clusterin</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_027285.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,585</td><td align="left" rowspan="1" colspan="1">1700029I01Rik</td><td align="left" rowspan="1" colspan="1">RIKEN cDNA 1700029I01 gene</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_177708.3</td><td align="left" rowspan="1" colspan="1">&#x02212;1,583</td><td align="left" rowspan="1" colspan="1">Rtn4rl1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">NM_016867.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,571</td><td align="left" rowspan="1" colspan="1">Semcap2</td><td align="left" rowspan="1" colspan="1">semaF cytoplasmic domain associated protein 2</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_009150.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,552</td><td align="left" rowspan="1" colspan="1">Selenbp2;Selenbp1</td><td align="left" rowspan="1" colspan="1">selenium binding protein 2;selenium binding protein 1</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_177820.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,484</td><td align="left" rowspan="1" colspan="1">9130218O11Rik</td><td align="left" rowspan="1" colspan="1">RIKEN cDNA 9130218O11 gene</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_009726.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,423</td><td align="left" rowspan="1" colspan="1">Atp7a</td><td align="left" rowspan="1" colspan="1">ATPase, Cu&#x0002b;&#x0002b; transporting, alpha polypeptide</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_026416.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,393</td><td align="left" rowspan="1" colspan="1">S100a16</td><td align="left" rowspan="1" colspan="1">S100 calcium binding protein A16</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_023422.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,390</td><td align="left" rowspan="1" colspan="1">Hist1h2bc</td><td align="left" rowspan="1" colspan="1">histone 1, H2bc</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_009760.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,378</td><td align="left" rowspan="1" colspan="1">Bnip3</td><td align="left" rowspan="1" colspan="1">BCL2/adenovirus E1B 19kDa-interacting protein 1, NIP3</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_030037.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,334</td><td align="left" rowspan="1" colspan="1">Mospd3</td><td align="left" rowspan="1" colspan="1">motile sperm domain containing 3</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_010149.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,323</td><td align="left" rowspan="1" colspan="1">Epor</td><td align="left" rowspan="1" colspan="1">erythropoietin receptor</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_172296.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,305</td><td align="left" rowspan="1" colspan="1">Dmrta2</td><td align="left" rowspan="1" colspan="1">doublesex and mab-3 related transcription factor like family A2</td></tr><tr><td align="left" rowspan="1" colspan="1">AK076923.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,305</td><td align="left" rowspan="1" colspan="1">Ppm1b</td><td align="left" rowspan="1" colspan="1">protein phosphatase 1B, magnesium dependent, beta isoform</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_026030.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,298</td><td align="left" rowspan="1" colspan="1">Eif2s2</td><td align="left" rowspan="1" colspan="1">eukaryotic translation initiation factor 2, subunit 2 (beta)</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_194268.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,294</td><td align="left" rowspan="1" colspan="1">Onecut2</td><td align="left" rowspan="1" colspan="1">one cut domain, family member 2</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_008926.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,293</td><td align="left" rowspan="1" colspan="1">Prkg2</td><td align="left" rowspan="1" colspan="1">protein kinase, cGMP-dependent, type II</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_026565.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,291</td><td align="left" rowspan="1" colspan="1">9430083G14Rik</td><td align="left" rowspan="1" colspan="1">RIKEN cDNA 9430083G14 gene</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_025949.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,279</td><td align="left" rowspan="1" colspan="1">Rps6ka6</td><td align="left" rowspan="1" colspan="1">ribosomal protein S6 kinase polypeptide 6</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_009242.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,264</td><td align="left" rowspan="1" colspan="1">Sparc</td><td align="left" rowspan="1" colspan="1">secreted acidic cysteine rich glycoprotein</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_178405.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,256</td><td align="left" rowspan="1" colspan="1">Atp1a2</td><td align="left" rowspan="1" colspan="1">ATPase, Na&#x0002b;/K&#x0002b; transporting, alpha 2 polypeptide</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_007874.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,237</td><td align="left" rowspan="1" colspan="1">Dp1</td><td align="left" rowspan="1" colspan="1">deleted in polyposis 1</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_026793.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,236</td><td align="left" rowspan="1" colspan="1">Myct1</td><td align="left" rowspan="1" colspan="1">myc target 1</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_177603.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,228</td><td align="left" rowspan="1" colspan="1">Frat2</td><td align="left" rowspan="1" colspan="1">frequently rearranged in advanced T-cell lymphomas 2</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_025836.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,224</td><td align="left" rowspan="1" colspan="1">M6prbp1</td><td align="left" rowspan="1" colspan="1">mannose-6-phosphate receptor binding protein 1</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_028535.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,224</td><td align="left" rowspan="1" colspan="1">1700049E17Rik</td><td align="left" rowspan="1" colspan="1">RIKEN cDNA 1700049E17 gene</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_026358.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,221</td><td align="left" rowspan="1" colspan="1">4930583H14Rik</td><td align="left" rowspan="1" colspan="1">RIKEN cDNA 4930583H14 gene</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_172132.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,218</td><td align="left" rowspan="1" colspan="1">Jmjd2b</td><td align="left" rowspan="1" colspan="1">jumonji domain containing 2B</td></tr><tr><td align="left" rowspan="1" colspan="1">AK005820.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,210</td><td align="left" rowspan="1" colspan="1">Rabl5</td><td align="left" rowspan="1" colspan="1">RAB, member of RAS oncogene family-like 5</td></tr><tr><td align="left" rowspan="1" colspan="1">AK049314.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,193</td><td align="left" rowspan="1" colspan="1">Trim27</td><td align="left" rowspan="1" colspan="1">tripartite motif protein 27</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_017367.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,188</td><td align="left" rowspan="1" colspan="1">Ccni</td><td align="left" rowspan="1" colspan="1">cyclin I</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_009814.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,180</td><td align="left" rowspan="1" colspan="1">Casq2</td><td align="left" rowspan="1" colspan="1">calsequestrin 2</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_009101.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,174</td><td align="left" rowspan="1" colspan="1">Rras</td><td align="left" rowspan="1" colspan="1">Harvey rat sarcoma oncogene, subgroup R</td></tr><tr><td align="left" rowspan="1" colspan="1">AK003039.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,174</td><td align="left" rowspan="1" colspan="1">Gltp</td><td align="left" rowspan="1" colspan="1">glycolipid transfer protein</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_008467.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,172</td><td align="left" rowspan="1" colspan="1">Kpna4</td><td align="left" rowspan="1" colspan="1">karyopherin (importin) alpha 4</td></tr><tr><td align="left" rowspan="1" colspan="1">BC038145.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,172</td><td align="left" rowspan="1" colspan="1">BC002199</td><td align="left" rowspan="1" colspan="1">cDNA sequence BC002199</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_133780.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,168</td><td align="left" rowspan="1" colspan="1">Tpr</td><td align="left" rowspan="1" colspan="1">translocated promoter region</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_177798.3</td><td align="left" rowspan="1" colspan="1">&#x02212;1,157</td><td align="left" rowspan="1" colspan="1">Frs2</td><td align="left" rowspan="1" colspan="1">fibroblast growth factor receptor substrate 2</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_008906.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,153</td><td align="left" rowspan="1" colspan="1">Ppgb</td><td align="left" rowspan="1" colspan="1">protective protein for beta-galactosidase</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_015818.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,152</td><td align="left" rowspan="1" colspan="1">Hs6st1</td><td align="left" rowspan="1" colspan="1">heparan sulfate 6-O-sulfotransferase 1</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_009113.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,152</td><td align="left" rowspan="1" colspan="1">S100a13</td><td align="left" rowspan="1" colspan="1">S100 calcium binding protein A13</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_009344.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,148</td><td align="left" rowspan="1" colspan="1">Phlda1</td><td align="left" rowspan="1" colspan="1">pleckstrin homology-like domain, family A, member 1</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_019675.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,148</td><td align="left" rowspan="1" colspan="1">Stmn4</td><td align="left" rowspan="1" colspan="1">stathmin-like 4</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_146141.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,147</td><td align="left" rowspan="1" colspan="1">1110013G13Rik</td><td align="left" rowspan="1" colspan="1">RIKEN cDNA 1110013G13 gene</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_009140.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,146</td><td align="left" rowspan="1" colspan="1">Cxcl2</td><td align="left" rowspan="1" colspan="1">chemokine (C-X-C motif) ligand 2</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_173788.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,145</td><td align="left" rowspan="1" colspan="1">Npr2</td><td align="left" rowspan="1" colspan="1">natriuretic peptide receptor 2</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_021274.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,144</td><td align="left" rowspan="1" colspan="1">Cxcl10</td><td align="left" rowspan="1" colspan="1">chemokine (C-X-C motif) ligand 10</td></tr><tr><td align="left" rowspan="1" colspan="1">AK052456.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,142</td><td align="left" rowspan="1" colspan="1">D430026P16Rik</td><td align="left" rowspan="1" colspan="1">RIKEN cDNA D430026P16 gene</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_153399.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,140</td><td align="left" rowspan="1" colspan="1">Syne1</td><td align="left" rowspan="1" colspan="1">synaptic nuclear envelope 1</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_011756.3</td><td align="left" rowspan="1" colspan="1">&#x02212;1,136</td><td align="left" rowspan="1" colspan="1">Zfp36</td><td align="left" rowspan="1" colspan="1">zinc finger protein 36</td></tr><tr><td align="left" rowspan="1" colspan="1">AK083556.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,136</td><td align="left" rowspan="1" colspan="1">Fst</td><td align="left" rowspan="1" colspan="1">follistatin</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_026033.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,122</td><td align="left" rowspan="1" colspan="1">Odag</td><td align="left" rowspan="1" colspan="1">ocular development associated gene</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_031997.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,121</td><td align="left" rowspan="1" colspan="1">Tmem2</td><td align="left" rowspan="1" colspan="1">transmembrane protein 2</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_178772.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,117</td><td align="left" rowspan="1" colspan="1">B230106I24Rik</td><td align="left" rowspan="1" colspan="1">RIKEN cDNA B230106I24 gene</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_011353.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,112</td><td align="left" rowspan="1" colspan="1">Serf1</td><td align="left" rowspan="1" colspan="1">small EDRK-rich factor 1</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_021398.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,110</td><td align="left" rowspan="1" colspan="1">Slc43a3</td><td align="left" rowspan="1" colspan="1">solute carrier family 43, member 3</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_027482.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,095</td><td align="left" rowspan="1" colspan="1">5730508B09Rik</td><td align="left" rowspan="1" colspan="1">RIKEN cDNA 5730508B09 gene</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_133777.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,087</td><td align="left" rowspan="1" colspan="1">Ube2s</td><td align="left" rowspan="1" colspan="1">ubiquitin-conjugating enzyme E2S</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_012057.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,083</td><td align="left" rowspan="1" colspan="1">Irf5</td><td align="left" rowspan="1" colspan="1">interferon regulatory factor 5</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_013660.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,080</td><td align="left" rowspan="1" colspan="1">Sema4d</td><td align="left" rowspan="1" colspan="1">sema domain, immunoglobulin domain (Ig), (semaphorin) 4D</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_146260.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,080</td><td align="left" rowspan="1" colspan="1">Tmie</td><td align="left" rowspan="1" colspan="1">transmembrane inner ear</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_153068.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,075</td><td align="left" rowspan="1" colspan="1">Ehd2</td><td align="left" rowspan="1" colspan="1">EH-domain containing 2</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_138584.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,074</td><td align="left" rowspan="1" colspan="1">Spg21</td><td align="left" rowspan="1" colspan="1">spastic paraplegia 21 homolog (human)</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_011295.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,073</td><td align="left" rowspan="1" colspan="1">Rps12</td><td align="left" rowspan="1" colspan="1">ribosomal protein S12</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_030696.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,071</td><td align="left" rowspan="1" colspan="1">Slc16a3</td><td align="left" rowspan="1" colspan="1">solute carrier family 16 (monocarboxylic acid transporters), member 3</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_130903.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,068</td><td align="left" rowspan="1" colspan="1">Cd209c</td><td align="left" rowspan="1" colspan="1">CD209c antigen</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_020586.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,068</td><td align="left" rowspan="1" colspan="1">5031400M07Rik</td><td align="left" rowspan="1" colspan="1">RIKEN cDNA 5031400M07 gene</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_031997.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,067</td><td align="left" rowspan="1" colspan="1">Tmem2</td><td align="left" rowspan="1" colspan="1">transmembrane protein 2</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_010789.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,065</td><td align="left" rowspan="1" colspan="1">Meis1</td><td align="left" rowspan="1" colspan="1">myeloid ecotropic viral integration site 1</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_011498.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,065</td><td align="left" rowspan="1" colspan="1">Bhlhb2</td><td align="left" rowspan="1" colspan="1">basic helix-loop-helix domain containing, class B2</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_025290.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,063</td><td align="left" rowspan="1" colspan="1">Tsga2</td><td align="left" rowspan="1" colspan="1">testis specific gene A2</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_139144.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,063</td><td align="left" rowspan="1" colspan="1">Ogt</td><td align="left" rowspan="1" colspan="1">O-linked N-acetylglucosamine (GlcNAc) transferase (UDP-N-acetylglucosamine:polypeptide-N-acetylglucosaminyl transferase)</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_009895.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,059</td><td align="left" rowspan="1" colspan="1">Cish</td><td align="left" rowspan="1" colspan="1">cytokine inducible SH2-containing protein</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_011171.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,057</td><td align="left" rowspan="1" colspan="1">Procr</td><td align="left" rowspan="1" colspan="1">protein C receptor, endothelial</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_019880.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,056</td><td align="left" rowspan="1" colspan="1">Mtch1</td><td align="left" rowspan="1" colspan="1">mitochondrial carrier homolog 1 (C. elegans)</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_010658.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,056</td><td align="left" rowspan="1" colspan="1">Mafb</td><td align="left" rowspan="1" colspan="1">v-maf musculoaponeurotic fibrosarcoma oncogene family, protein B (avian)</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_011046.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,054</td><td align="left" rowspan="1" colspan="1">Furin</td><td align="left" rowspan="1" colspan="1">furin (paired basic amino acid cleaving enzyme)</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_011252.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,053</td><td align="left" rowspan="1" colspan="1">Rbmx</td><td align="left" rowspan="1" colspan="1">RNA binding motif protein, X chromosome</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_007585.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,047</td><td align="left" rowspan="1" colspan="1">Anxa2</td><td align="left" rowspan="1" colspan="1">annexin A2</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_025348.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,045</td><td align="left" rowspan="1" colspan="1">Ndufa3</td><td align="left" rowspan="1" colspan="1">NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 3</td></tr><tr><td align="left" rowspan="1" colspan="1">BC028655.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,044</td><td align="left" rowspan="1" colspan="1">Solt</td><td align="left" rowspan="1" colspan="1">SoxLZ/Sox6 leucine zipper binding protein in testis</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_028279.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,043</td><td align="left" rowspan="1" colspan="1">Naalad2</td><td align="left" rowspan="1" colspan="1">N-acetylated alpha-linked acidic dipeptidase 2</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_018865.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,040</td><td align="left" rowspan="1" colspan="1">Wisp1</td><td align="left" rowspan="1" colspan="1">WNT1 inducible signaling pathway protein 1</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_178751.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,038</td><td align="left" rowspan="1" colspan="1">A730041O15Rik</td><td align="left" rowspan="1" colspan="1">RIKEN cDNA A730041O15 gene</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_029688.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,037</td><td align="left" rowspan="1" colspan="1">Npn3</td><td align="left" rowspan="1" colspan="1">neoplastic progression 3</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_013692.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,031</td><td align="left" rowspan="1" colspan="1">Tieg1</td><td align="left" rowspan="1" colspan="1">TGFB inducible early growth response 1</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_013525.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,025</td><td align="left" rowspan="1" colspan="1">Gas5</td><td align="left" rowspan="1" colspan="1">growth arrest specific 5</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_175395.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,023</td><td align="left" rowspan="1" colspan="1">1700001A24Rik; 6330578E17Rik</td><td align="left" rowspan="1" colspan="1">RIKEN cDNA 1700001A24 gene;RIKEN cDNA 6330578E17 gene</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_019704.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,023</td><td align="left" rowspan="1" colspan="1">C78915</td><td align="left" rowspan="1" colspan="1">expressed sequence C78915</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_010234.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,022</td><td align="left" rowspan="1" colspan="1">Fos</td><td align="left" rowspan="1" colspan="1">FBJ osteosarcoma oncogene</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_011594.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,020</td><td align="left" rowspan="1" colspan="1">Timp2</td><td align="left" rowspan="1" colspan="1">tissue inhibitor of metalloproteinase 2</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_198420.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,019</td><td align="left" rowspan="1" colspan="1">D15Wsu169e</td><td align="left" rowspan="1" colspan="1">DNA segment, Chr 15, Wayne State University 169, expressed</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_008662.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,018</td><td align="left" rowspan="1" colspan="1">Myo6</td><td align="left" rowspan="1" colspan="1">myosin VI</td></tr><tr><td align="left" rowspan="1" colspan="1">AK033214.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,018</td><td align="left" rowspan="1" colspan="1">Gfm</td><td align="left" rowspan="1" colspan="1">G elongation factor</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_010885.2</td><td align="left" rowspan="1" colspan="1">&#x02212;1,013</td><td align="left" rowspan="1" colspan="1">Ndufa2</td><td align="left" rowspan="1" colspan="1">NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 2</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_027287.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,007</td><td align="left" rowspan="1" colspan="1">Dnajb4</td><td align="left" rowspan="1" colspan="1">DnaJ (Hsp40) homolog, subfamily B, member 4</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_133942.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,006</td><td align="left" rowspan="1" colspan="1">AA960558</td><td align="left" rowspan="1" colspan="1">expressed sequence AA960558</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_007664.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,005</td><td align="left" rowspan="1" colspan="1">Cdh2</td><td align="left" rowspan="1" colspan="1">cadherin 2</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_027189.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,004</td><td align="left" rowspan="1" colspan="1">Gemin7</td><td align="left" rowspan="1" colspan="1">gem (nuclear organelle) associated protein 7</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_009627.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1,001</td><td align="left" rowspan="1" colspan="1">Adm</td><td align="left" rowspan="1" colspan="1">adrenomedullin</td></tr></tbody></table><table-wrap-foot><fn id="nt101"><label/><p>This Table represent a selection of annotated genes upregulated (red) and downregulated (green) by estradiol, sensitive to LEF-1 mutant. The list contains only those &#x0201c;annotated genes&#x0201d; with a log2R higher or lower than 1. <bold>A</bold> represent the control cell line (N2a-m-<italic>mock transfected</italic>). <bold>B</bold> represents the cell line transfected with <italic>delta-56</italic>-LEF-1. In the table <bold>es</bold>t, represents treatment with estradiol; and <bold>Wnt</bold>, treatment with Wnt3a.</p></fn><fn id="nt102"><label/><p>We labeled two genes (<bold><italic>plasminogen</italic></bold><bold> and </bold><bold><italic>LEF-1</italic></bold>) regulated by estradiol or by Wnt3a , both were subsequently validated at protein level.</p></fn></table-wrap-foot></table-wrap><p>As shown in <xref ref-type="fig" rid="pone-0005153-g009">figure 9A</xref>, the log<sub>2</sub> R of some of these genes was low, and certainly, the protein expression showed no differences. Considering that the low level of detection may be related with the short exposure time (60 minutes), we extended the treatment to confirm the differential regulation of some genes mediated by &#x00394;56LEF-1. Accordingly, we treated the cell lines with estradiol or Wnt3a over a period of 24 h to allow for the accumulation of the protein. Soluble fraction, or nuclear fractions, or conditioned medium was obtained from treated cells and we analyzed the genes identified as differentially expressed in the microarray (when antibodies were available) as well as some genes known to be regulated by Wnt, such as E-cadherin, &#x003b2;-catenin or cyclin D.</p><p>Our data confirmed some of the variations in the genes described. Interestingly, MMP-2 secretion was most prominent in Wnt-treated cells whereas the proactive form appeared to be secreted prominently by &#x00394;56LEF-1/N2a-m cells. Similarly, &#x003b2;-catenin displayed weaker protein expression in &#x00394;56LEF-1/N2a-m cells, independently of the treatment.</p><p>Finally, a second set of genes were found, those that respond to estradiol (and/or Wnt) in control cells and whose regulation was modified by the presence of &#x00394;56LEF-1. Indeed, longer treatment enabled clear differences to be detected at the protein level in genes such as N-cadherin and Cyclin D2. Our data indicated that N-cadherin was upregulated by estradiol and Wnt, and that the expression of &#x00394;56LEF-1 almost completely blocked these effects (<xref ref-type="fig" rid="pone-0005153-g009">Figure 9B</xref>). While Cyclin D2 behaved similarly, Cyclin D1 appeared to be unchanged and unaffected by treatments (<xref ref-type="fig" rid="pone-0005153-g009">Figure 9B</xref>). On the other hand, E-cadherin was upregulated by estradiol in control cells (Group <bold>A</bold>), whereas the presence of &#x00394;56LEF-1 generated an uncontrolled upregulation. This result revealed an important role for LEF-1 in estrogen-regulated E-cadherin expression.</p></sec></sec><sec id="s3"><title>Discussion</title><p>Estrogens may act through different mechanisms, the best known of which involves their capacity to directly bind to and dimerize estrogen receptors (ERs). This hormone-protein complex can either bind directly to promoter estrogen response elements (EREs), or act as a cofactor at non-ERE sites through the interaction with other DNA-binding elements, such as AP-1, or c-Jun <xref ref-type="bibr" rid="pone.0005153-Beato1">&#x0005b;5&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005153-Tora1">&#x0005b;25&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005153-Truss1">&#x0005b;26&#x0005d;</xref>. A second mode of action is associated with the so-called &#x0201c;non genomic&#x0201d; or &#x0201c;rapid&#x0201d; actions, that include the activation of PKC, G-protein-coupled receptors, ERKs and PI3K/Akt in different cell systems <xref ref-type="bibr" rid="pone.0005153-Singh1">&#x0005b;8&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005153-Yu1">&#x0005b;27&#x0005d;</xref>. Regarding this theme, we recently reported that ER&#x003b1; forms a protein complex with GSK3 and &#x003b2;-catenin in the hippocampus of ovariectomized rats; the action of estradiol dissociated &#x003b2;-catenin from the complex in a manner that was clearly correlated with the inhibition of GSK3 <xref ref-type="bibr" rid="pone.0005153-CardonaGomez1">&#x0005b;12&#x0005d;</xref>. The interaction of ER&#x003b1; with GSK3 does not appear to be specific for neurons and indeed, it has recently been demonstrated that ER&#x003b1; is also phosphorylated and modulated by GSK3 in other cell types <xref ref-type="bibr" rid="pone.0005153-Kouzmenko1">&#x0005b;28&#x0005d;</xref>.</p><sec id="s3a"><title>Estradiol, through a &#x0201c;rapid response&#x0201d;, activated the pathway Akt/GSK3, stabilized &#x003b2;-catenin, and modulates TCF-mediated transcription, in neurons</title><p>We had initially found that the inhibition of GSK3 by estradiol was correlated with the stabilization of &#x003b2;-catenin. Thus, our first aim here was to determine whether the pool of &#x003b2;-catenin regulated by estradiol acts as a co-transcriptional modulator using canonical TCF-mediated transcription or alternatively, whether the stabilization of &#x003b2;-catenin plays some other role. With this aim, we selected a neuronal cell line easily amenable to transfection with a TCF-reporter: the N2a-m cell line which expresses the &#x003b1; and &#x003b2; ER receptors and accumulates nuclear ER when treated with estradiol. Significantly, we detected a complex of &#x003b2;-catenin and GSK3 in these cells following exposure to either ER&#x003b1; or ER&#x003b2;. When N2a-m or cortical neurons were treated with estradiol, we detected a similar biochemical response with an increase of GSK3 serine phosphorylation as well as the stabilization of &#x003b2;-catenin. This inhibition of GSK3 was time- and concentration-dependent, and these data are in essence similar to those described in the hippocampus of ovariectomiced rats after estradiol treatment, or in hippocampal neurons <xref ref-type="bibr" rid="pone.0005153-CardonaGomez1">&#x0005b;12&#x0005d;</xref>.</p><p>Taking into account these initial results, the question arose as to whether &#x003b2;-catenin stabilized by estradiol might modulate transcription. It is believed that &#x003b2;-catenin has two different and complementary roles in cells; it may contribute to the cell-cell adhesion or it may act as a co-transcriptional regulator of the TCF family <xref ref-type="bibr" rid="pone.0005153-Moon1">&#x0005b;16&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005153-Barolo1">&#x0005b;19&#x0005d;</xref>. Our data first showed that estradiol activated TCF-mediated transcription at concentrations of 10&#x000d7;10<sup>&#x02212;9</sup> M. This nuclear activation of <italic>luciferase</italic> was time- and concentration-dependent, it was maximal at 10&#x02013;20&#x000d7;10<sup>&#x02212;8</sup> M, and it could be abolished by the ER antagonist ICI 182780. Similar, but slightly weaker transcriptional activation could be obtained with the ER&#x003b1;-selective agonist, PPT (5&#x02013;10 nM), as well with the ER&#x003b2;-selective agonist, DPN (5&#x02013;10 nM). All these data strongly suggested that estradiol stabilizes &#x003b2;-catenin through ER&#x003b1; and ER&#x003b2;, and that at least a portion of this protein pool can activate transcription. This transcriptional activation depended on the phosphorylation status of &#x003b2;-catenin. Indeed, the highest levels of transcription were obtained with a mutated form of &#x003b2;-catenin (S33Y) that was virtually unaffected by estradiol. These data raise the question as to whether this TCF- &#x003b2;-catenin mediated transcription is similar to that obtained with Wnt proteins.</p><p>We have also showed that estradiol may activate transcription from a portion of the <italic>engrailed-1</italic> promoter that contains well characterized TCF elements (pENP1-<italic>luc</italic>) (McGrew et al. 1999), and also activate transcription in primary neurons derived from mice transgenic for a TCF-&#x003b2;-galactosidase reporter driving the expression of a <italic>luciferase</italic> reporter. It is important to remember that the estradiol-dependent transcription mediated by pENP1-<italic>luc</italic> is severely inhibited by the expression a LEF-1 truncated-mutant (&#x00394;56LEF-1) <xref ref-type="bibr" rid="pone.0005153-Hsu1">&#x0005b;23&#x0005d;</xref>. We found that estradiol slightly augmented the formation of DNA-TCF complexes, a similar effect to that produced by exposure to Wnt3a. This transcriptional activation is dependent on LEF-1, since antibodies against LEF-1 can disrupt DNA-complex formation. Furthermore, the presence of &#x00394;56LEF-1 almost completely prevented estradiol-mediated transcription.</p><p>It was recently demonstrated that estradiol regulates LEF-1 and Tcf3, and more importantly, that a complex containing ER&#x003b1; and Tcf3/LEF-1 may be immunoprecipitated from mouse uterus extracts <xref ref-type="bibr" rid="pone.0005153-Ray1">&#x0005b;29&#x0005d;</xref>. Accordingly, it was proposed that a complex composed of ER&#x003b1;/&#x003b2;-catenin/Tcf-3 is an important part of the estradiol response in this tissue. Although we cannot completely rule out this possibility (particularly since we did not use the same methodology), in our experiments LEF-1 was not immunoprecipitated when antibodies against either ER&#x003b1; or &#x003b2; were used. Only antibodies against LEF-1 prevented the formation of a DNA-protein complex in EMSA assays, unlike antibodies against Tcf 3 or ER&#x003b1;. Indeed, the initial cytoplasmic ER&#x003b1;/&#x003b2;-catenin/GSK3 complex appears to be different, with the complex in uterus being arranged (assembled?) after hormone addition, while in neural cells and neurons the complex is detected even prior to hormone treatment.</p><p>Further studies will be required to clarify whether the same ER&#x003b1;/&#x003b2;-catenin/Tcf-3 complex observed in the uterus is also present in neurons or in some specific brain regions. It will be interesting analyzing other possible components that might mediate the effect of the estrogen receptor on TCF/LEF-1 transcription, such as transducin beta-like protein 1 (TBL1) and its highly related family member TBLR1 <xref ref-type="bibr" rid="pone.0005153-Li1">&#x0005b;30&#x0005d;</xref>; among many others (see reviewed in <xref ref-type="bibr" rid="pone.0005153-Moon1">&#x0005b;16&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005153-Barolo1">&#x0005b;19&#x0005d;</xref>). A different point worthy of mention is that we detected multiple ER&#x003b1; bands in N2A cell extracts and after estradiol treatment only some of them appear to move into the nuclear fraction. This observation opens some interesting questions about the molecular nature of these multiple bands and why only some of them are mobilized. We are currently initiating the study of these ER&#x003b1; isoform/s in order to clarify the different possibilities suggested by the bibliography (isoform <italic>versus</italic> proteolysis??) <xref ref-type="bibr" rid="pone.0005153-Flouriot1">&#x0005b;31&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005153-Metivier1">&#x0005b;32&#x0005d;</xref>.</p><p>Several publications have recently emerged in which new elements have been described that regulate the Wnt-&#x003b2;-catenin pathway. For example, c-Jun forms a complex with &#x003b2;-catenin and Dvl in the nucleus, and this association regulates the transcriptional activity of &#x003b2;-catenin <xref ref-type="bibr" rid="pone.0005153-Gan1">&#x0005b;33&#x0005d;</xref>. Moreover, Rac1-JNK2 appears to act as a novel modulator of &#x003b2;-catenin mediated transcription <xref ref-type="bibr" rid="pone.0005153-Wu1">&#x0005b;34&#x0005d;</xref>. Thus, the complex regulation of &#x003b2;-catenin is becoming more evident, as it is not only modulated through its cellular distribution or phosphorylation, but also by the proteins with which it associates. Here, we describe a novel pathway that regulates &#x003b2;-catenin/TCF activity through a ligand, estradiol, using at least some of the components of the original Wnt pathway.</p></sec><sec id="s3b"><title>Is the gene expression through LEF-1/&#x003b2;-catenin estradiol-mediated similar to those triggered by Wnt?</title><p>To determine more specifically whether estradiol can regulate gene expression using the TCF/LEF-1-&#x003b2;-catenin system in a way similar to that of Wnt3a, we generated N2a-m cells stably transfected with &#x00394;56LEF-1 cDNA. By analyzing the gene expression profile of these cell lines on an Aplied Biosystems Mouse Genome Survey Microarray, we detected 223 genes modified by estradiol; whereas Wnt3a modified 303 genes, sensitive to &#x00394;56LEF-1 (see <xref ref-type="table" rid="pone-0005153-t001"><bold>Table 1</bold></xref>, containing only the annotated sequences).</p><p>To validate these changes, at the protein level, we had to extend the treatment period and as a result, we selected some representative genes from our array, such as <italic>Plg</italic> as well as some genes that have been previously associated with Wnt stimuli, such as E-Cadherin <xref ref-type="bibr" rid="pone.0005153-Jamora1">&#x0005b;35&#x0005d;</xref>, Cyclin D <xref ref-type="bibr" rid="pone.0005153-Shtutman1">&#x0005b;36&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005153-Sansom1">&#x0005b;38&#x0005d;</xref>, c-myc <xref ref-type="bibr" rid="pone.0005153-He1">&#x0005b;39&#x0005d;</xref>, LEF-1 <xref ref-type="bibr" rid="pone.0005153-Hovanes1">&#x0005b;40&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005153-Filali1">&#x0005b;41&#x0005d;</xref> and TCF-1 <xref ref-type="bibr" rid="pone.0005153-Roose1">&#x0005b;42&#x0005d;</xref>. We used commercially available antibodies to validate the changes in the levels of these proteins in the presence of &#x00394;56LEF-1 and/or the hormone or Wnt. Our data revealed two major types of response: first, those genes modified initially by the LEF-1 mutant background, such as Plasminogen, LEF-1 , &#x003b2;-catenin and MMP-2, and second, a group of genes which initially responded to estradiol, either positively or negatively, and additionally showed an increased response in the &#x00394;56LEF-1 cells, such as N-Cadherin, E-Cadherin and Cyclin D2. Indeed, the CyclinD2 promoter is clearly regulated by the estrogen receptor as well as by TCFs, although its responsiveness to Wnt proteins has also been assessed <xref ref-type="bibr" rid="pone.0005153-Shtutman1">&#x0005b;36&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005153-Sansom1">&#x0005b;38&#x0005d;</xref>. Our data indicate that in neurons, this gene may be regulated by both elements, at least in part <italic>via</italic> &#x003b2;-catenin/LEF-1.</p><p>Taken together, these data demonstrate the existence of a new pathway controlled by estradiol, at least in neurons. Our data show that this pathway contains some elements that may belong to the canonical Wnt-pathway. Indeed some reports indicate that estradiol may control the response of the Wnt pathway as an important part of its neuroprotective role. This neuroprotective response is mediated by increase of Wnt3a and inhibition of Dkk1 elevation, triggered after cerebral ischemia <xref ref-type="bibr" rid="pone.0005153-Zhang1">&#x0005b;43&#x0005d;</xref>. More work is now required to identify whether a similar mechanism is specific for certain types of brain insults or represents a more general mechanism. The analysis of our arrays (<xref ref-type="table" rid="pone-0005153-t001"><bold>Table 1</bold></xref>) supports the hypothesis that only part of the estradiol response sensitive to LEF-1, is similar to Wnt3a response sensitive to LEF-1. This open the possibility that in addition of collaborate with the Wnt response, estradiol may regulated a pool genes (&#x003b2;-catenin/LEF-1- directed), independently of Wnt status.</p></sec><sec id="s3c"><title>&#x0201c;Neuroprotective role&#x0201d; of estradiol and GSK3 inhibition</title><p>A complementary and important aspect of our data is that estradiol modulates the kinase activity of GSK3 irrespective of the neuronal source, and consequently the stabilization of &#x003b2;-catenin is an important event in these so called &#x0201c;non-genomic actions&#x0201d;. When considering the role of GSK3 and &#x003b2;-catenin in neurodegeneration <xref ref-type="bibr" rid="pone.0005153-Lucas1">&#x0005b;44&#x0005d;</xref>, such as in relation to Alzheimer's disease or ischemia, some of the functional effects of estradiol may, at least in part, represent an important physiological control of this kinase <xref ref-type="bibr" rid="pone.0005153-Xu1">&#x0005b;15&#x0005d;</xref>. We have to remember that in model systems of &#x003b2;-amyloid-mediated toxicity, similar concentrations of estradiol may protect neurons <xref ref-type="bibr" rid="pone.0005153-Xu1">&#x0005b;15&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005153-McCullough1">&#x0005b;45&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005153-Quintanilla1">&#x0005b;46&#x0005d;</xref>.</p><p>Estrogens play an important role in normal brain development <xref ref-type="bibr" rid="pone.0005153-ToranAllerand1">&#x0005b;47&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005153-Belcher1">&#x0005b;48&#x0005d;</xref>. In addition, this hormone appears to exert a more general neuroprotective effect such as in mouse models of Parkinson's disease <xref ref-type="bibr" rid="pone.0005153-Miller1">&#x0005b;49&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005153-Morissette1">&#x0005b;53&#x0005d;</xref> or after brain ischemia <xref ref-type="bibr" rid="pone.0005153-Culmsee1">&#x0005b;54&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005153-Simpkins1">&#x0005b;58&#x0005d;</xref>. In some ischemia models the estradiol&#x02013;mediated GSK3 response, appears to be JNK-Dkk1-dependent <xref ref-type="bibr" rid="pone.0005153-Zhang1">&#x0005b;43&#x0005d;</xref>, and we cannot discard this possibility in our neuronal system. However, our data indicate that the estradiol-mediated inhibition of GSK3 is PI3K-Akt dependent (O. Varea et al., unpublished data). It will be very important to determine whether the response that we observed is specific to &#x0201c;immature neurons&#x0201d; or whether it represents a more general mechanism.</p></sec></sec><sec sec-type="materials|methods" id="s4"><title>Materials and Methods</title><sec id="s4a"><title>Primary Cortical neurons and Neuroblastoma N2a-m</title><p>Mice were treated following the guidelines of Council of Europe Convention ETS123, recently revised as indicated in the Directive 86/609/EEC. In addition all protocols were approved by the institutional animal care and use committee. Cortical neurons were obtained from E18 mouse embryos after isolating the cortex in Ca<sup>2&#x0002b;</sup>- and Mg<sup>2&#x0002b;</sup>-free Hanks Buffer Salt Solution (HBSS 1&#x000d7;, GIBCO). Once 8&#x02013;10 embryonic cortices were obtained, they were finely cited, washed twice in HBSS 1&#x000d7; buffer,and incubated in 0.25&#x00025; trypsin (GIBCO) and 1 mg/ml DNAse (Roche) for 15 min at 37&#x000b0;C. Trypsin and DNAse were then eliminated by washing three times, with HBSS 1&#x000d7;, and the cut tissue was then triturated using a siliconized pipette. The cells were counted and plated in a poly-lysine coated (1 mg/ml, Sigma) 60 mm dish containing plating medium (MEM, 20&#x00025; Glucose, horse serum and antibiotics). After 3 hours plating, the medium was changed to phenol red-free Neurobasal medium supplemented with B-B27 GIBCO) and the neurons were maintained under these conditions for 2 days. Murine neuroblastoma N2a-m cells were grown at 37&#x000b0;C in 7&#x00025; CO<sub>2</sub>, in DMEM supplemented with 10&#x00025; fetal calf serum (GIBCO) and 2 mM glutamine.</p><sec id="s4a1"><title>Cell treatments</title><p>One day before treatment, the medium was changed to serum and phenol red free-medium The compounds used for treatments were: 17-&#x003b2;-estradiol (stored in ethanol at a concentration of 1 mM), ICI 182780 (Tocris, stored in dimethyl sulfoxide -DMSO- at 2 mM), Wnt3a recombinant protein (R&#x00026;D systems, dissolved in PBS-BSA 0.1&#x00025; and stored at 0.1 &#x000b5;g/&#x000b5;l), and the estrogen receptor agonists, 4,4&#x02032;,4&#x02033;-(propyl-&#x0005b;(1)H&#x0005d;-pyrazole-1,3,5-triyl) trisphenol (PPT, &#x003b1;-selective) and 2,3-bis (4-hydroxyphenyl) propionitrile (DPN (&#x003b2;-selective) agonists, both dissolved in ethanol. Different concentrations of these compounds were used as indicated for each experiment and the controls received the vehicle of each compound alone, ethanol in the case of estradiol, DMSO for ICI 182780 and PBS-BSA 0.1&#x00025; as control for Wnt3a. The final concentration of ICI 182780 used was depending on the concentration of estradiol, in a ICI/estradiol ratio of 100 times.</p></sec></sec><sec id="s4b"><title>Western Blotting and Antibodies</title><p>After two washes with PBS, cell extracts were prepared in lysis buffer containing 200 mM Hepes pH 7.4, 100 mM NaCl, 100 mM NaF, 1 mM Na<sub>3</sub>VO<sub>4</sub>, 5 mM EDTA, 1&#x00025; Triton and a protease inhibitor cocktail (Roche). The cells were left for 30 min on ice in this lysis buffer and then collected with a cell scraper. After adding loading buffer, the samples were boiled for 10 min and resolved by Tris/Glycine SDS-Polyacrylamide gel electrophoresis, and the proteins were then transferred to a nitrocellulose membrane (Amersham) in the presence of 20&#x00025; methanol and 0.1&#x00025; SDS. Non-specific signals were blocked by incubating the membrane in PBS-Tween-20 (PBT) and 5&#x00025; milk for 2 h. The antibodies used to probe the membranes were raised against: Ct ER&#x003b1; 1&#x02236;800 (MC-20, Santa Cruz), ER&#x003b2; 1&#x02236;1000 (H-150, Santa Cruz), GSK3 &#x003b1;/&#x003b2; 1&#x02236;1000 (Cell signalling), GSKPSer<sup>9, 21</sup> 1&#x02236;1000 (Cell Signalling), &#x003b2;-catenin 1&#x02236;800 (Transduction Labs), non-phospho &#x003b2;-catenin 1&#x02236;800 (Upstate), actin 1&#x02236;2000 (Sigma), LEF-1 HMG box 1&#x02236;800 (Sigma), cyclin D1 1&#x02236;1000 (Santa Cruz), cyclin D2 1&#x02236;1000 (MBL), N cadherin 1&#x02236;1000 (Sigma), E cadherin 1&#x02236;800 (Santa Cruz), MMP2 1&#x02236;200 (Santa Cruz), nucleolin 1&#x02236;1000 (Santa Cruz), beta-galactosidase (ICN Biomed-Cappel), &#x003b2;-III tubulin (Chemicon). These antibodies were then detected with horseradish peroxidase conjugated secondary antibodies (Amersham) used at a dilution of 1&#x02236;5000.</p></sec><sec id="s4c"><title>Immunocytochemistry</title><p>To study the localization of proteins by immunocytochemistry, we fixed cells plated at low density with 4&#x00025; paraformaldehyde for 20 min at RT. After 3 washes for 10 min in PBS, fixed-cells were incubated with 50 mM NH<sub>4</sub>Cl and then blocked and permeabilized for 30 min with 1&#x00025; fetal calf serum and 0.1&#x00025; Triton-X-100 in PBS. The cells were incubated with the primary antibodies for 2 h at RT and after 3 washes with blocking solution, the secondary Alexa fluor-488 or 594 antibodies were added (1&#x02236;1000, Molecular Probes). The primary antibodies used were raised against &#x003b2;-catenin (1&#x02236;400, Transduction Labs) or ER&#x003b1; (1&#x02236;500, MC-20, Santa Cruz). To visualize the distribution of polymerized actin, fixed cells were stained with phalloidin conjugated to Alexa 488 or 594, as indicated in each experiment (1&#x02236;100, Molecular Probes). Coverslips were mounted with Fluoromount G (Southern Biotechnology Associates, Inc) and photographs were taken on a confocal microscope (LSM 510 META, Zeiss).</p></sec><sec id="s4d"><title>Plasmids and Transient expression in N2a-m cells</title><p>The plasmids used for transient expression were: pTOPFlash (Upstate), containing three copies of the consensus sequence recognized by the TCF/LEF transcription factors (CCTTTGATC) and with the c-Fos promoter driving the expression of luciferase gene; pFOPFlash (Upstate) that contains three non-functional copies of the TCF/LEF binding site (CCTTTGGCC); and EGFP-N1 encodes an enhanced green-fluorescent protein used to quantify the efficiency of transfection when co-transfected with TOP/FOPFlash. N2a-m cells were transfected using LipofectAMINE 2000 (Invitrogen) according to the manufacturer's instructions. For transfection, 600,000 cells were plated in a 60 mm-culture dish with growth medium and the day before transfection, the medium was changed to DMEM without FCS or antibiotics. Co-transfections were performed with 2 &#x000b5;l LipofectAMINE (Invitrogen) and 1 &#x000b5;g of total-DNA (0.75 &#x000b5;g TOP/FOP plus 0.25 &#x000b5;g EGFP-N1). After transfection, the medium was changed to DMEM without phenol red or FCS, supplemented with an antibiotic cocktail. Treatments were started 48 h after transfection to coincide with the maximum expression levels of the co-transfected proteins.</p><p>Other plasmids used for transfection were: empty pcDNA3 as an internal control; &#x00394;45 &#x003b2;-catenin, a deleted form of &#x003b2;-catenin lacking the N-terminal (kindly provided by Dr. R. Moon); and LEF-1&#x00394;56 (kindly provided by Dr. R. Grosschedl) that expresses a form of LEF-1 that is unable to interact with &#x003b2;-catenin.</p></sec><sec id="s4e"><title>Primary Cortical Neuron Nucleofection</title><p>The TOPFlash plasmid was introduced into cortical neurons by nucleofection (Basic Nucleofector Kit for Primary Mammalian Neural cells, Amaxa Bioscience) according to the manufacturer instructions. A total of 3 &#x000b5;g TOPFlash plus 1 &#x000b5;g GFP was introduced into 4&#x000d7;10<sup>6</sup> cells, and both luciferase activity and the efficiency of nucleofection were analyzed after 2 days in culture.</p></sec><sec id="s4f"><title>Assay of luciferase activity</title><p>After treatment of the TOPFlash transfected N2a-m cells, they were incubated in 60 mm plate with 1 ml of TEN buffer (40 mM Tris-HCl pH 7.5, 10 mM EDTA, 150 mM NaCl) for 15 min at RT to detach the cells from the dish. Once the cells had been collected and pelleted, they were resuspended in 100 &#x000b5;l of lysis-buffer (100 mM Potassium Phosphate buffer ph 7.8, 1 mM DTT, 0.5&#x00025; Triton) and incubated on ice for 30 min. The lysate was then centrifuged at 4&#x000b0;C, 5 min to eliminate aggregates and the supernatant was transferred to a fresh tube. A fraction of this supernatant was resolved by electrophoresis to check the cellular mass and the amount of protein was quantified. The rest of the cell extract was used to measure the luciferase activity in 200 &#x000b5;l of luciferase buffer (25 mM Glycyl-glycine, 15 mM MgSO<sub>4</sub>, 5 mM ATP, 1 mM DTT, 100 &#x000b5;g/ml BSA) mixed with 20 &#x000b5;l of the cell extract. The luciferine reaction substrate (Promega) was used at a concentration of 1 mM (dissolved in sterile water), and we determined the quantity of luciferase expressed in the cells by measuring the reaction at 560 nm with a luminometer (Monolight&#x000ae; 2010, Analytical Luminescence Laboratory). The values obtained correspond to the mean and standard deviation of three sets of independent experiments. To analyze the induction of &#x003b2;-catenin co-activator function, the values were normalized to controls (corresponding to the ratio transfected/non treated cells).</p></sec><sec id="s4g"><title>Immunoprecipitation</title><p>Inmunoprecipitation assays we carried out on a confluent culture dish of N2a-m cells that were collected in 0.5 ml of immunoprecipitation buffer A (1&#x00025; Triton X-100, 150 mM NaCl, 10 mM Tris pH 7.4, 1 mM EDTA pH 8, 1 mM EGTA pH 8, 0.2 mM sodium-<italic>ortho</italic>-vanadate, 0.2 mM PMSF, 0,5&#x00025; NP-40). After incubation on ice for 30 min, the lysate was centrifuged (16000&#x000d7;g at 4&#x000b0;C, 15 min) to eliminate possible aggregates. The supernatant (100 &#x000b5;l of total native lysate) was incubated in the following buffer: 2&#x00025; Triton X-100, 20 mM Tris pH 7.4, 2 mM EDTA pH 8, 2 mM EGTA pH 8, 0.4 mM sodium <italic>ortho</italic>-vanadate, 0.4 mM PMSF, 1&#x00025; NP-40) in the presence of 5 &#x000b5;g of anti-ER&#x003b1; antibody in a total volume of 500 &#x000b5;l. The mixture was incubated for 1 h at 4&#x000b0;C and subsequently, 10 ul of Protein A-Agarose solution (Sigma) was added and incubated at 4&#x000b0;C for 30 min with agitation. The agarose beads were recovered by centrifuging at 16000&#x000d7;g for 4 min at 4&#x000b0;C, and the pellet was washed three times with buffer A and centrifuged (16000&#x000d7;g at 4&#x000b0;C). Finally, the pellet was resuspended in 30 &#x000b5;l of 2&#x000d7; electrophoresis sample buffer (250 mM Tris pH 6.8, 4&#x00025; SDS, 10&#x00025; glycerol, 0.006&#x00025; bromophenol blue, 2&#x00025; &#x003b2;-mercaptoethanol), boiled for 10 min and loaded onto an SDS-PAGE gel to be analyzed by western blotting.</p></sec><sec id="s4h"><title>Purification of cortical nuclei</title><p>After the dissection of the cortex from 12&#x02013;16 E18 embryos, the tissue was homogenized in buffer A (0.32 M sucrose, 10 mM Tris pH 7.4, 3 mM MgCl<sub>2</sub> supplemented with 0.1&#x00025; Triton-X-100, protease inhibitors, DTT and PMSF). The homogenate was centrifuged at 2500 rpm for 10 min at 4&#x000b0;C, the supernatant was discarded and the pellet was resuspended in buffer A without Triton, and centrifuged in the same conditions. The pellet obtained was resuspended in buffer B (the same as buffer A, but containing 1.9 M sucrose instead of 0.32 M) and homogenized again. The extract was carefully loaded over buffer C (buffer A, but with 2 M sucrose) and spun at 12000 rpm for 60 min at 4&#x000b0;C. The final pellet of the nuclei was resuspended in 50 &#x000b5;l of buffer A, 150 &#x000b5;l of protein extraction buffer (20 mM Tris pH 7.4, 400 mM NaCl, 0.5 mM EDTA pH 8, 0.5 mM EGTA pH 8, 2 mM MgCl<sub>2</sub>) was added and the mix was incubated on ice for 30 min. To finally obtain the soluble fraction of nuclear proteins, the extract was centrifuged at 35000 rpm for 30 min at 4&#x000b0;C and the protein concentration in the extracts was measure using the Lowry reaction.</p></sec><sec id="s4i"><title>Electrophoretic Mobility Shift Assays (EMSA)</title><p>To obtain nuclear extracts of N2a-m or cortical neurons, cells were grown in serum free-DMEM, without phenol red, to 80&#x00025; confluence. After washing twice with PBS, 400 &#x000b5;l of EMSA buffer A was added to each P100 dish (10 mM Tris pH 7.5, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA,1 mM DTT, PMSF, 1 &#x000b5;M Na<sub>3</sub>VO<sub>4</sub> and protease inhibitor cocktail). Once two confluent P100 mm dishes were collected in a fresh tube (8 P60 mm in the case of cortical primary neurons), cells were incubated for 15 min on ice and then 40 &#x000b5;l of 10&#x00025; NP-40 was added and vortexed for 20 sec. The supernatant was centrifuged for 30 sec at 15000 rpm to obtain the cytoplasm fraction. Once dry-resuspended the pellet containing the nuclei, 50 &#x000b5;l of EMSA buffer B (20 mM Tris pH 7.5, 400 mM NaCl, 0.5 mM EDTA, 0.5 mM EGTA, 2 mM MgCl<sub>2</sub>, 1 mM DTT, 0.5 mM PMSF, 1 &#x000b5;M Na<sub>3</sub>VO<sub>4</sub> and protease inhibitor cocktail) was added at 4&#x000b0;C with vigorous shaking for 15 min. The samples were then centrifuged for 30 sec at 15000 rpm and the supernatant recovered as the nuclear extract. The EMSA assay was performed as described previously <xref ref-type="bibr" rid="pone.0005153-Garcia1">&#x0005b;59&#x0005d;</xref>. Protein-primer binding was carried out with 20 &#x000b5;g of nuclear proteins during 30 min at RT and a similar amount of each primer (50.000 cpm/&#x000b5;l annealed primer) was added to the reaction at a concentration of 1 mg/ml (sequence forward: <named-content content-type="gene">5&#x02032;-GTCGCCCTTTGATCTTACC-3&#x02032;</named-content>, reverse: <named-content content-type="gene">5&#x02032;-GTCGGGTAAGATCAAAGGG-3&#x02032;</named-content>, synthetic oligonucleotides from Invitrogen). When antibodies were used in the EMSA assays, 2 &#x000b5;g of antibody against TCF-1-X, TCF-3-X and LEF-1-X (from Santa Cruz) and 1 &#x000b5;g of antibody against &#x003b2;-catenin (Transduction Labs) or 0.8 &#x000b5;g of antibody against ER&#x003b1; (MC-20, Santa Cruz) was added 20 min after the binding reaction had terminated. Competition experiments were performed to recognize the specific bands corresponding to the TCF/LEF-1-DNA complex using TCF/LEF containing the mutated sequence (sequence forward: <named-content content-type="gene">5&#x02032;-GTCGCCCTTTGGCCTTACC-3&#x02032;</named-content>, reverse: <named-content content-type="gene">5&#x02032;-GTCGGGTAAGGCCAAAGGG-3&#x02032;</named-content>) and unlabelled-wild type TCF/LEF sequence at different final concentrations (20 ng and 100 ng). In all cases, the binding reaction was carried out at a final concentration of 60&#x02013;65 mM KCl and in the presence of poly dIdC (1 mg/ml) and CHAPS (20&#x00025;). The results of the binding reaction were analyzed in 4.5&#x00025; acrylamide/bisacrylamide gels run at constant 130 V and dried (80&#x000b0;C, 1 h).</p></sec><sec id="s4j"><title>Total RNA isolation and RT-PCR quantification</title><p>Total RNA was isolated from N2a-m cells from a confluent P100 mm dish or from 3 P60 mm dishes in the case of cortical neurons. An additional set of RNA was obtained from N2a-m stable-transfected with pcDNA3-LEF-1 56 or with empty-pcDNA3, either untreated or exposed to estradiol or Wnt3a. RNA was obtained using TRIzol (GIBCO) and it was finally resuspended in sterile-DEPC treated water. The RNA concentration was determined by spectrophotometry at 260 nm, and its integrity was checked using a Bioanalyzer Chip (Agilent). First strand cDNA synthesis was performed on 2 &#x000b5;g of RNA and using the reverse primer as the priming site, hybridized at 37&#x02013;40&#x000b0;C during 5 min before the remaining reaction components were added: MMLV Reverse-Transcriptase, 2.5 mM DTT, and RT-Buffer (GIBCO) with RNAsin and 10 mM dNTPs. Elongation was performed at 37&#x000b0;C (optimal temperature for the RT enzyme) and the reaction was finally heated to 94&#x000b0;C (5 min) to inactivate the RT enzyme. RT-PCR amplification was performed to analyze cyclin D1, c-myc, actin, &#x003b2;-galactosidase, actin and GADPH expression using the Master SYBR Green I mix (Roche) with 2 mM MgCl<sub>2</sub> in a lightcycler instrument (Roche Molecular Biochemicals). PCR was performed under optimal conditions for each primer pair. The oligonucleotide sequences and PCR conditions used were as follows: <bold>actin</bold>: 94&#x000b0;C-15 s, 57&#x000b0;C-10 s, 72&#x000b0;C-20 s (forward: <named-content content-type="gene">5&#x02032;-TGTTTGAGACCTTCAACACC-3&#x02032;</named-content>; reverse: <named-content content-type="gene">5&#x02032;-TAGGAGCCAGAGCAGTAATC-3&#x02032;</named-content>; 600 bp), <bold>cyclin D1:</bold> 94&#x000b0;C-15 s, 55&#x000b0;C-10 s, 72&#x000b0;C-20 s (forward: <named-content content-type="gene">5&#x02032;-CACAACGCACTTTCTTTCCA-3&#x02032;</named-content>; reverse: <named-content content-type="gene">5&#x02032;-GACCAGCCTCTTCCTCCAC-3&#x02032;</named-content>; 164 bp), <bold>&#x003b2;-galactosidase:</bold> 94&#x000b0;C-15 s, 64&#x000b0;C-5 s, 72&#x000b0;C-15 s (forward: <named-content content-type="gene">5&#x02032;-ATCCTCTGCATGGTCAGGTC-3&#x02032;</named-content>, reverse: <named-content content-type="gene">5&#x02032;-CGTGGCCTGATTCATTCC-3&#x02032;</named-content>; 315 bp).</p></sec><sec id="s4k"><title>Transgenic mice</title><p>The transgenic mice containing the lacZ gene under the control of three consensus TCF/LEF-binding motifs upstream of the c-fos promoter have been described previously <xref ref-type="bibr" rid="pone.0005153-DasGupta1">&#x0005b;21&#x0005d;</xref> (strain Tg(Fos-LacZ)34Efu/J, JAX&#x000ae;Mice, The Jackson Laboratory) . The genotype of the mice was checked using the following primers and PCR conditions: lacZ rose gene (forward: <named-content content-type="gene">5&#x02032;-ATCCTCTGCATGGTCAGGTC-3&#x02032;</named-content>, reverse: <named-content content-type="gene">5&#x02032;-CGTGGCCTGATTCATTCC-3&#x02032;</named-content>, 315 bp), endogenous gene (forward: <named-content content-type="gene">5&#x02032;-CAAATGTTGCTTGTCTGGTG-3&#x02032;</named-content>; reverse: <named-content content-type="gene">5&#x02032;-GTCAGTCGAGTGCACAGTTT-3&#x02032;</named-content>, 210 bp). The mouse colony was maintained in heterozygosis and it was necessary to check each embryo when used for primary neuronal cultures. Accordingly, a portion of the cortex was placed in a mixture containing &#x0201c;Dye Solution&#x0201d; (5 mM K<sub>4</sub>&#x0005b;Fe(CN)<sub>6</sub>&#x0005d;.3H<sub>2</sub>0, 5 mM K<sub>3</sub>&#x0005b;Fe(CN)<sub>6</sub>&#x0005d;, 2 mM MgCl<sub>2</sub>) and X-Gal (1 mg/ml).</p></sec><sec id="s4l"><title>Microarray analysis</title><p>Gene expression profiles were generated using Applied Biosystems Mouse Genome Survey Microarray. Total RNA pools were cleaned using the RNeasy kit from Qiagen (Hilden, Germany). Digoxigenin-UTP labeled cDNA probes were generated and linearly amplified from 1 &#x000b5;g of each RNA pool using Applied Biosystems Chemiluminescent RT-IVT labeling Kit. Microarray hybridization, chemiluminescence detection, image acquisition and analysis were done according to Applied Biosystems protocols and the 1700 Chemiluminescent Microarray Analyzer.</p><p>Applied Biosystems Expression System software was used to extract Assay Signal, and Assay Signal to Noise ratio values from the microarray images. Bad spots flagged by the software were removed from the analysis. The Assay Signal of the represented genes was <bold><italic>log</italic></bold> transformed, loess-normalized (<ext-link ext-link-type="uri" xlink:href="http://www.bioconductor.org">http://www.bioconductor.org</ext-link>) and further filtered by standard Expression Array System Signal to Noise threshold (S/N greater than 3 in at least one sample). The expression profiles of the two control populations (N2a-m stable-cell lines with or without &#x00394;LEF-1) were compared with the corresponding population, treated with either estradiol or Wnt3a.</p></sec></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0005153.s001"><label>Figure S1</label><caption><p>N2a-m cells express both the ER&#x003b1; and ER{lower caes beta} isoforms of the estrogen receptor and they respond to estradiol. Immunocytochemistry with anti-ER&#x003b1; and ER&#x003b2; identified a different cytoplasmic location for the two isoforms in both cell lines. While ER&#x003b1; presented was diffusely distributed throughout the cytosol and nucleus, and it accumulated in the nucleus after the addition of estradiol (A&#x02013;B). ER&#x003b2; distribution was more heterogeneous and it could be found in aggregates, diffusely distributed in the cytosol or in the nucleus(C&#x02013;D). The addition of estradiol (B and D) increases the immunoreactivity against two receptors in the nucleus. Images were analyzed by confocal microscopy and western blotting confirmed the expression of both isoforms in total cell extracts from control cells.</p><p>(9.68 MB EPS)</p></caption><media xlink:href="pone.0005153.s001.eps" mimetype="application" mime-subtype="postscript"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0005153.s002"><label>Figure S2</label><caption><p>Distribution of &#x003b2;-catenin after exposure of N2a-m cells to estradiol does not reveal the translocation of &#x003b2;-catenin to the nucleus. Cell fractions corresponding to the soluble, membrane and nuclear fractions were analyzed in control and estradiol treated cells. Neither 30 nor 60 min exposure to estradiol provoked the nuclear accumulation of &#x003b2;-catenin, statistically significant. In contrast, recruitment of &#x003b2;-catenin to the membrane fraction was more evident. We also checked the movement of ER&#x003b1; as a control of the assay, which clearly accumulated in the nuclear fraction (see <xref ref-type="fig" rid="pone-0005153-g008">Figure 8</xref>).</p><p>(2.36 MB EPS)</p></caption><media xlink:href="pone.0005153.s002.eps" mimetype="application" mime-subtype="postscript"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0005153.s003"><label>Figure S3</label><caption><p>N2a-m cells are responsive to Wnt3a protein. (A)- N2a-m cells respond to Wnt3a (20 ng/ml) with the accumulation of &#x003b2;-catenin and with a maximal effect observed after 90&#x02013;120 minutes. (B)- The transcriptional activity of &#x003b2;-catenin was analyzed with the TCF-luc reporter. Luciferase activity was calculated at different concentrations of Wnt3a protein, as indicated above, and Wnt3a produced a significant increase in &#x003b2;-catenin/TCF dependent transcription. Asterisk represents P value from Student's t-test: &#x0002a; (P&#x02264;0.05), when compared the two Wnt concentrations; and &#x0002a;&#x0002a; (P&#x02264;0.01) when compared with control.</p><p>(1.61 MB EPS)</p></caption><media xlink:href="pone.0005153.s003.eps" mimetype="application" mime-subtype="postscript"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0005153.s004"><label>Figure S4</label><caption><p>Neither ER&#x003b1; nor TCF-3 antibodies modify the migration of nuclear protein extracts from N2a-m cells exposed to estradiol or Wnt3a. Nuclear protein extracts were obtained from control or estradiol/Wnt3a treated cells as indicated in each lane. The incubation with specific antibodies against ER&#x003b1; or TCF3 did not produce a higher molecular weight band that migrated more slowly than that previously identified as a TCF-DNA complex, nor did they prevent the formation of the complex.</p><p>(2.50 MB EPS)</p></caption><media xlink:href="pone.0005153.s004.eps" mimetype="application" mime-subtype="postscript"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We are grateful to Dr. Filip Lim, Dr. J. Diaz-Nido and Dr. I Anton for corrections to the manuscript and for thoughtful discussions. We also wish to thank Dr P. Medrano for providing us with antibodies and advice, and to Drs P. Bovolenta, R. Moom, R. Grosschedl and B. Vogelstein for providing us with some of the DNA constructs used in this project. We especially thank Drs. A. Nieto and Dr. C. Garcia for advice and help improving the EMSA technique.</p></ack><ref-list><title>References</title><ref id="pone.0005153-Wang1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>CN</given-names></name><name><surname>Chi</surname><given-names>CW</given-names></name><name><surname>Lin</surname><given-names>YL</given-names></name><name><surname>Chen</surname><given-names>CF</given-names></name><name><surname>Shiao</surname><given-names>YJ</given-names></name></person-group><year>2001</year><article-title>The neuroprotective effects of phytoestrogens on amyloid beta protein- induced toxicity are mediated by abrogating the activation of caspase cascade in rat cortical neurons.</article-title><source>J Biol Chem</source><volume>(7)</volume><fpage>5287</fpage><lpage>5295</lpage><pub-id pub-id-type="pmid">11083861</pub-id></citation></ref><ref id="pone.0005153-GarciaSegura1"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Segura</surname><given-names>LM</given-names></name><name><surname>Azcoitia</surname><given-names>I</given-names></name><name><surname>DonCarlos</surname><given-names>LL</given-names></name></person-group><year>2001</year><article-title>Neuroprotection by estradiol.</article-title><source>Prog Neurobiol</source><volume>63(1)</volume><fpage>29</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">11040417</pub-id></citation></ref><ref id="pone.0005153-Wise1"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wise</surname><given-names>P</given-names></name></person-group><year>2003</year><article-title>Estradiol exerts neuroprotective actions against ischemic brain injury: insights derived from animal models.</article-title><source>Endocrine</source><volume>21(1)</volume><fpage>11</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">12777698</pub-id></citation></ref><ref id="pone.0005153-McKenna1"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McKenna</surname><given-names>NJ</given-names></name><name><surname>O'Malley</surname><given-names>BW</given-names></name></person-group><year>2001</year><article-title>Nuclear receptors, coregulators, ligands, and selective receptor modulators: making sense of the patchwork quilt.</article-title><source>Ann N Y Acad Sci</source><volume>949</volume><fpage>3</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">11795367</pub-id></citation></ref><ref id="pone.0005153-Beato1"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beato</surname><given-names>M</given-names></name><name><surname>Herrlich</surname><given-names>P</given-names></name><name><surname>Schutz</surname><given-names>G</given-names></name></person-group><year>1995</year><article-title>Steroid hormone receptors: many actors in search of a plot.</article-title><source>Cell</source><volume>83(6)</volume><fpage>851</fpage><lpage>857</lpage><pub-id pub-id-type="pmid">8521509</pub-id></citation></ref><ref id="pone.0005153-Kuiper1"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kuiper</surname><given-names>GG</given-names></name><name><surname>Enmark</surname><given-names>E</given-names></name><name><surname>Pelto-Huikko</surname><given-names>M</given-names></name><name><surname>Nilsson</surname><given-names>S</given-names></name><name><surname>Gustafsson</surname><given-names>JA</given-names></name></person-group><year>1996</year><article-title>Cloning of a novel receptor expressed in rat prostate and ovary.</article-title><source>Proc Natl Acad Sci USA</source><volume>93(12)</volume><fpage>5925</fpage><lpage>5930</lpage><pub-id pub-id-type="pmid">8650195</pub-id></citation></ref><ref id="pone.0005153-Beato2"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beato</surname><given-names>M</given-names></name><name><surname>Klug</surname><given-names>J</given-names></name></person-group><year>2000</year><article-title>Steroid hormone receptors: an update.</article-title><source>Hum Reprod Update</source><volume>6(3)</volume><fpage>225</fpage><lpage>236</lpage><pub-id pub-id-type="pmid">10874567</pub-id></citation></ref><ref id="pone.0005153-Singh1"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>M</given-names></name><name><surname>Setalo</surname><given-names>G</given-names><suffix>Jr</suffix></name><name><surname>Guan</surname><given-names>X</given-names></name><name><surname>Warren</surname><given-names>M</given-names></name><name><surname>Toran-Allerand</surname><given-names>CD</given-names></name></person-group><year>1999</year><article-title>Estrogen-induced activation of mitogen-activated protein kinase in cerebral cortical explants: convergence of estrogen and neurotrophin signaling pathways.</article-title><source>J Neurosci</source><volume>19(4)</volume><fpage>1179</fpage><lpage>1188</lpage><pub-id pub-id-type="pmid">9952396</pub-id></citation></ref><ref id="pone.0005153-Cordey1"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cordey</surname><given-names>M</given-names></name><name><surname>Gundimeda</surname><given-names>U</given-names></name><name><surname>Gopalakrishna</surname><given-names>R</given-names></name><name><surname>Pike</surname><given-names>CJ</given-names></name></person-group><year>2003</year><article-title>Estrogen activates protein kinase C in neurons: role in neuroprotection.</article-title><source>J Neurochem</source><volume>84(6)</volume><fpage>1340</fpage><lpage>1348</lpage><pub-id pub-id-type="pmid">12614334</pub-id></citation></ref><ref id="pone.0005153-Honda1"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Honda</surname><given-names>K</given-names></name><name><surname>Sawada</surname><given-names>H</given-names></name><name><surname>Kihara</surname><given-names>T</given-names></name><name><surname>Urushitani</surname><given-names>M</given-names></name><name><surname>Nakamizo</surname><given-names>T</given-names></name><etal/></person-group><year>2000</year><article-title>Phosphatidylinositol 3-kinase mediates neuroprotection by estrogen in cultured cortical neurons.</article-title><source>J Neurosci Res</source><volume>60(3)</volume><fpage>321</fpage><lpage>327</lpage><pub-id pub-id-type="pmid">10797534</pub-id></citation></ref><ref id="pone.0005153-Mendez1"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mendez</surname><given-names>P</given-names></name><name><surname>Azcoitia</surname><given-names>I</given-names></name><name><surname>Garcia-Segura</surname><given-names>LM</given-names></name></person-group><year>2003</year><article-title>Estrogen receptor alpha forms estrogen-dependent multimolecular complexes with insulin-like growth factor receptor and phosphatidylinositol 3-kinase in the adult rat brain.</article-title><source>Brain Res Mol Brain Res</source><volume>112(1&#x02013;2)</volume><fpage>170</fpage><lpage>176</lpage><pub-id pub-id-type="pmid">12670715</pub-id></citation></ref><ref id="pone.0005153-CardonaGomez1"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cardona-Gomez</surname><given-names>P</given-names></name><name><surname>Perez</surname><given-names>M</given-names></name><name><surname>Avila</surname><given-names>J</given-names></name><name><surname>Garcia-Segura</surname><given-names>LM</given-names></name><name><surname>Wandosell</surname><given-names>F</given-names></name></person-group><year>2004</year><article-title>Estradiol inhibits GSK3 and regulates interaction of estrogen receptors, GSK3, and beta-catenin in the hippocampus.</article-title><source>Mol Cell Neurosci</source><volume>25(3)</volume><fpage>363</fpage><lpage>373</lpage><pub-id pub-id-type="pmid">15033165</pub-id></citation></ref><ref id="pone.0005153-Demay1"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Demay</surname><given-names>F</given-names></name><name><surname>De Monti</surname><given-names>M</given-names></name><name><surname>Tiffoche</surname><given-names>C</given-names></name><name><surname>Vaillant</surname><given-names>C</given-names></name><name><surname>Thieulant</surname><given-names>ML</given-names></name></person-group><year>2001</year><article-title>Steroid-independent activation of ER by GnRH in gonadotrope pituitary cells.</article-title><source>Endocrinology</source><volume>142(8)</volume><fpage>3340</fpage><lpage>3347</lpage><pub-id pub-id-type="pmid">11459776</pub-id></citation></ref><ref id="pone.0005153-Pap1"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pap</surname><given-names>M</given-names></name><name><surname>Cooper</surname><given-names>GM</given-names></name></person-group><year>1998</year><article-title>Role of glycogen synthase kinase-3 in the phosphatidylinositol 3- Kinase/Akt cell survival pathway.</article-title><source>J Biol Chem</source><volume>273(32)</volume><fpage>19929</fpage><lpage>19932</lpage><pub-id pub-id-type="pmid">9685326</pub-id></citation></ref><ref id="pone.0005153-Xu1"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Gouras</surname><given-names>GK</given-names></name><name><surname>Greenfield</surname><given-names>JP</given-names></name><name><surname>Vincent</surname><given-names>B</given-names></name><name><surname>Naslund</surname><given-names>J</given-names></name><etal/></person-group><year>1998</year><article-title>Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides.</article-title><source>Nat Med</source><volume>4(4)</volume><fpage>447</fpage><lpage>451</lpage><pub-id pub-id-type="pmid">9546791</pub-id></citation></ref><ref id="pone.0005153-Moon1"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moon</surname><given-names>RT</given-names></name><name><surname>Kohn</surname><given-names>AD</given-names></name><name><surname>De Ferrari</surname><given-names>GV</given-names></name><name><surname>Kaykas</surname><given-names>A</given-names></name></person-group><year>2004</year><article-title>WNT and beta-catenin signalling: diseases and therapies.</article-title><source>Nat Rev Genet</source><volume>5(9)</volume><fpage>691</fpage><lpage>701</lpage><pub-id pub-id-type="pmid">15372092</pub-id></citation></ref><ref id="pone.0005153-Mulholland1"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mulholland</surname><given-names>DJ</given-names></name><name><surname>Dedhar</surname><given-names>S</given-names></name><name><surname>Coetzee</surname><given-names>GA</given-names></name><name><surname>Nelson</surname><given-names>CC</given-names></name></person-group><year>2005</year><article-title>Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know?</article-title><source>Endocr Rev</source><volume>26(7)</volume><fpage>898</fpage><lpage>915</lpage><pub-id pub-id-type="pmid">16126938</pub-id></citation></ref><ref id="pone.0005153-Arce1"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arce</surname><given-names>L</given-names></name><name><surname>Yokoyama</surname><given-names>NN</given-names></name><name><surname>Waterman</surname><given-names>ML</given-names></name></person-group><year>2006</year><article-title>Diversity of LEF/TCF action in development and disease.</article-title><source>Oncogene</source><volume>25(57)</volume><fpage>7492</fpage><lpage>7504</lpage><pub-id pub-id-type="pmid">17143293</pub-id></citation></ref><ref id="pone.0005153-Barolo1"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barolo</surname><given-names>S</given-names></name></person-group><year>2006</year><article-title>Transgenic Wnt/TCF pathway reporters: all you need is Lef?</article-title><source>Oncogene</source><volume>25(57)</volume><fpage>7505</fpage><lpage>7511</lpage><pub-id pub-id-type="pmid">17143294</pub-id></citation></ref><ref id="pone.0005153-Bienz1"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bienz</surname><given-names>M</given-names></name></person-group><year>2005</year><article-title>beta-catenin: a pivot between cell adhesion and Wnt signalling.</article-title><source>Curr Biol</source><volume>15(2)</volume><fpage>R64</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">15668160</pub-id></citation></ref><ref id="pone.0005153-DasGupta1"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>DasGupta</surname><given-names>R</given-names></name><name><surname>Fuchs</surname><given-names>E</given-names></name></person-group><year>1999</year><article-title>Multiple roles for activated LEF/TCF transcription complexes during hair follicle development and differentiation.</article-title><source>Development</source><volume>126(20)</volume><fpage>4557</fpage><lpage>4568</lpage><pub-id pub-id-type="pmid">10498690</pub-id></citation></ref><ref id="pone.0005153-McGrew1"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McGrew</surname><given-names>LL</given-names></name><name><surname>Takemaru</surname><given-names>K</given-names></name><name><surname>Bates</surname><given-names>R</given-names></name><name><surname>Moon</surname><given-names>RT</given-names></name></person-group><year>1999</year><article-title>Direct regulation of the Xenopus engrailed-2 promoter by the Wnt signaling pathway, and a molecular screen for Wnt-responsive genes, confirm a role for Wnt signaling during neural patterning in Xenopus.</article-title><source>Mech Dev</source><volume>87(1&#x02013;2)</volume><fpage>21</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">10495268</pub-id></citation></ref><ref id="pone.0005153-Hsu1"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>SC</given-names></name><name><surname>Galceran</surname><given-names>J</given-names></name><name><surname>Grosschedl</surname><given-names>R</given-names></name></person-group><year>1998</year><article-title>Modulation of transcriptional regulation by LEF-1 in response to Wnt-1 signaling and association with beta-catenin.</article-title><source>Mol Cell Biol</source><volume>18(8)</volume><fpage>4807</fpage><lpage>4818</lpage><pub-id pub-id-type="pmid">9671490</pub-id></citation></ref><ref id="pone.0005153-Galceran1"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Galceran</surname><given-names>J</given-names></name><name><surname>Miyashita-Lin</surname><given-names>EM</given-names></name><name><surname>Devaney</surname><given-names>E</given-names></name><name><surname>Rubenstein</surname><given-names>JL</given-names></name><name><surname>Grosschedl</surname><given-names>R</given-names></name></person-group><year>2000</year><article-title>Hippocampus development and generation of dentate gyrus granule cells is regulated by LEF1.</article-title><source>Development</source><volume>127(3)</volume><fpage>469</fpage><lpage>482</lpage><pub-id pub-id-type="pmid">10631168</pub-id></citation></ref><ref id="pone.0005153-Tora1"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tora</surname><given-names>L</given-names></name><name><surname>White</surname><given-names>J</given-names></name><name><surname>Brou</surname><given-names>C</given-names></name><name><surname>Tasset</surname><given-names>D</given-names></name><name><surname>Webster</surname><given-names>N</given-names></name><etal/></person-group><year>1989</year><article-title>The human estrogen receptor has two independent nonacidic transcriptional activation functions.</article-title><source>Cell</source><volume>59(3)</volume><fpage>477</fpage><lpage>487</lpage><pub-id pub-id-type="pmid">2805068</pub-id></citation></ref><ref id="pone.0005153-Truss1"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Truss</surname><given-names>M</given-names></name><name><surname>Beato</surname><given-names>M</given-names></name></person-group><year>1993</year><article-title>Steroid hormone receptors: interaction with deoxyribonucleic acid and transcription factors.</article-title><source>Endocr Rev</source><volume>14(4)</volume><fpage>459</fpage><lpage>479</lpage><pub-id pub-id-type="pmid">8223341</pub-id></citation></ref><ref id="pone.0005153-Yu1"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Rajala</surname><given-names>RV</given-names></name><name><surname>McGinnis</surname><given-names>JF</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Anderson</surname><given-names>RE</given-names></name><etal/></person-group><year>2004</year><article-title>Involvement of insulin/phosphoinositide 3-kinase/Akt signal pathway in 17 beta-estradiol-mediated neuroprotection.</article-title><source>J Biol Chem</source><volume>279(13)</volume><fpage>13086</fpage><lpage>13094</lpage><pub-id pub-id-type="pmid">14711819</pub-id></citation></ref><ref id="pone.0005153-Kouzmenko1"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kouzmenko</surname><given-names>AP</given-names></name><name><surname>Takeyama</surname><given-names>K</given-names></name><name><surname>Ito</surname><given-names>S</given-names></name><name><surname>Furutani</surname><given-names>T</given-names></name><name><surname>Sawatsubashi</surname><given-names>S</given-names></name><etal/></person-group><year>2004</year><article-title>Wnt/beta-catenin and estrogen signaling converge in vivo.</article-title><source>J Biol Chem</source><volume>279(39)</volume><fpage>40255</fpage><lpage>40258</lpage><pub-id pub-id-type="pmid">15304487</pub-id></citation></ref><ref id="pone.0005153-Ray1"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ray</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Das</surname><given-names>SK</given-names></name></person-group><year>2008</year><article-title>Cooperative Control via Lef-1/Tcf-3 and ER{alpha} for Uterine Gene Regulation by Estrogen.</article-title><source>Mol Endocrinol</source><fpage>1125</fpage><lpage>1140</lpage><pub-id pub-id-type="pmid">18202148</pub-id></citation></ref><ref id="pone.0005153-Li1"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>CY</given-names></name></person-group><year>2008</year><article-title>TBL1-TBLR1 and beta-catenin recruit each other to Wnt target-gene promoter for transcription activation and oncogenesis.</article-title><source>Nat Cell Biol</source><volume>10(2)</volume><fpage>160</fpage><lpage>169</lpage><pub-id pub-id-type="pmid">18193033</pub-id></citation></ref><ref id="pone.0005153-Flouriot1"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Flouriot</surname><given-names>G</given-names></name><name><surname>Brand</surname><given-names>H</given-names></name><name><surname>Denger</surname><given-names>S</given-names></name><name><surname>Metivier</surname><given-names>R</given-names></name><name><surname>Kos</surname><given-names>M</given-names></name><etal/></person-group><year>2000</year><article-title>Identification of a new isoform of the human estrogen receptor-alpha (hER-alpha) that is encoded by distinct transcripts and that is able to repress hER-alpha activation function 1.</article-title><source>Embo J</source><volume>19(17)</volume><fpage>4688</fpage><lpage>4700</lpage><pub-id pub-id-type="pmid">10970861</pub-id></citation></ref><ref id="pone.0005153-Metivier1"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Metivier</surname><given-names>R</given-names></name><name><surname>Penot</surname><given-names>G</given-names></name><name><surname>Carmouche</surname><given-names>RP</given-names></name><name><surname>Hubner</surname><given-names>MR</given-names></name><name><surname>Reid</surname><given-names>G</given-names></name><etal/></person-group><year>2004</year><article-title>Transcriptional complexes engaged by apo-estrogen receptor-alpha isoforms have divergent outcomes.</article-title><source>Embo J</source><volume>23(18)</volume><fpage>3653</fpage><lpage>3666</lpage><pub-id pub-id-type="pmid">15343269</pub-id></citation></ref><ref id="pone.0005153-Gan1"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gan</surname><given-names>XQ</given-names></name><name><surname>Wang</surname><given-names>JY</given-names></name><name><surname>Xi</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>ZL</given-names></name><name><surname>Li</surname><given-names>YP</given-names></name><etal/></person-group><year>2008</year><article-title>Nuclear Dvl, c-Jun, beta-catenin, and TCF form a complex leading to stabilization of beta-catenin-TCF interaction.</article-title><source>J Cell Biol</source><volume>180(6)</volume><fpage>1087</fpage><lpage>1100</lpage><pub-id pub-id-type="pmid">18347071</pub-id></citation></ref><ref id="pone.0005153-Wu1"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Tu</surname><given-names>X</given-names></name><name><surname>Joeng</surname><given-names>KS</given-names></name><name><surname>Hilton</surname><given-names>MJ</given-names></name><name><surname>Williams</surname><given-names>DA</given-names></name><etal/></person-group><year>2008</year><article-title>Rac1 activation controls nuclear localization of beta-catenin during canonical Wnt signaling.</article-title><source>Cell</source><volume>133(2)</volume><fpage>340</fpage><lpage>353</lpage><pub-id pub-id-type="pmid">18423204</pub-id></citation></ref><ref id="pone.0005153-Jamora1"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jamora</surname><given-names>C</given-names></name><name><surname>DasGupta</surname><given-names>R</given-names></name><name><surname>Kocieniewski</surname><given-names>P</given-names></name><name><surname>Fuchs</surname><given-names>E</given-names></name></person-group><year>2003</year><article-title>Links between signal transduction, transcription and adhesion in epithelial bud development.</article-title><source>Nature</source><volume>422(6929)</volume><fpage>317</fpage><lpage>322</lpage><pub-id pub-id-type="pmid">12646922</pub-id></citation></ref><ref id="pone.0005153-Shtutman1"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shtutman</surname><given-names>M</given-names></name><name><surname>Zhurinsky</surname><given-names>J</given-names></name><name><surname>Simcha</surname><given-names>I</given-names></name><name><surname>Albanese</surname><given-names>C</given-names></name><name><surname>D'Amico</surname><given-names>M</given-names></name><etal/></person-group><year>1999</year><article-title>The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway.</article-title><source>Proc Natl Acad Sci USA</source><volume>96(10)</volume><fpage>5522</fpage><lpage>5527</lpage><pub-id pub-id-type="pmid">10318916</pub-id></citation></ref><ref id="pone.0005153-Tetsu1"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tetsu</surname><given-names>O</given-names></name><name><surname>McCormick</surname><given-names>F</given-names></name></person-group><year>1999</year><article-title>Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells.</article-title><source>Nature</source><volume>398(6726)</volume><fpage>422</fpage><lpage>426</lpage><pub-id pub-id-type="pmid">10201372</pub-id></citation></ref><ref id="pone.0005153-Sansom1"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sansom</surname><given-names>OJ</given-names></name><name><surname>Reed</surname><given-names>KR</given-names></name><name><surname>van de Wetering</surname><given-names>M</given-names></name><name><surname>Muncan</surname><given-names>V</given-names></name><name><surname>Winton</surname><given-names>DJ</given-names></name><etal/></person-group><year>2005</year><article-title>Cyclin D1 is not an immediate target of beta-catenin following Apc loss in the intestine.</article-title><source>J Biol Chem</source><volume>280(31)</volume><fpage>28463</fpage><lpage>28467</lpage><pub-id pub-id-type="pmid">15946945</pub-id></citation></ref><ref id="pone.0005153-He1"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>TC</given-names></name><name><surname>Sparks</surname><given-names>AB</given-names></name><name><surname>Rago</surname><given-names>C</given-names></name><name><surname>Hermeking</surname><given-names>H</given-names></name><name><surname>Zawel</surname><given-names>L</given-names></name><etal/></person-group><year>1998</year><article-title>Identification of c-MYC as a target of the APC pathway.</article-title><source>Science</source><volume>281(5382)</volume><fpage>1509</fpage><lpage>1512</lpage><pub-id pub-id-type="pmid">9727977</pub-id></citation></ref><ref id="pone.0005153-Hovanes1"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hovanes</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>TW</given-names></name><name><surname>Munguia</surname><given-names>JE</given-names></name><name><surname>Truong</surname><given-names>T</given-names></name><name><surname>Milovanovic</surname><given-names>T</given-names></name><etal/></person-group><year>2001</year><article-title>Beta-catenin-sensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer.</article-title><source>Nat Genet</source><volume>28(1)</volume><fpage>53</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">11326276</pub-id></citation></ref><ref id="pone.0005153-Filali1"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Filali</surname><given-names>M</given-names></name><name><surname>Cheng</surname><given-names>N</given-names></name><name><surname>Abbott</surname><given-names>D</given-names></name><name><surname>Leontiev</surname><given-names>V</given-names></name><name><surname>Engelhardt</surname><given-names>JF</given-names></name></person-group><year>2002</year><article-title>Wnt-3A/beta-catenin signaling induces transcription from the LEF-1 promoter.</article-title><source>J Biol Chem</source><volume>277(36)</volume><fpage>33398</fpage><lpage>33410</lpage><pub-id pub-id-type="pmid">12052822</pub-id></citation></ref><ref id="pone.0005153-Roose1"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roose</surname><given-names>J</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name></person-group><year>1999</year><article-title>TCF transcription factors: molecular switches in carcinogenesis.</article-title><source>Biochim Biophys Acta</source><volume>1424(2&#x02013;3)</volume><fpage>M23</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">10528152</pub-id></citation></ref><ref id="pone.0005153-Zhang1"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>QG</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Khan</surname><given-names>M</given-names></name><name><surname>Mahesh</surname><given-names>V</given-names></name><name><surname>Brann</surname><given-names>DW</given-names></name></person-group><year>2008</year><article-title>Role of Dickkopf-1, an antagonist of the Wnt/beta-catenin signaling pathway, in estrogen-induced neuroprotection and attenuation of tau phosphorylation.</article-title><source>J Neurosci</source><volume>28(34)</volume><fpage>8430</fpage><lpage>8441</lpage><pub-id pub-id-type="pmid">18716201</pub-id></citation></ref><ref id="pone.0005153-Lucas1"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lucas</surname><given-names>JJ</given-names></name><name><surname>Hernandez</surname><given-names>F</given-names></name><name><surname>Gomez-Ramos</surname><given-names>P</given-names></name><name><surname>Moran</surname><given-names>MA</given-names></name><name><surname>Hen</surname><given-names>R</given-names></name><etal/></person-group><year>2001</year><article-title>Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice.</article-title><source>Embo J</source><volume>20(1&#x02013;2)</volume><fpage>27</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">11226152</pub-id></citation></ref><ref id="pone.0005153-McCullough1"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McCullough</surname><given-names>LD</given-names></name><name><surname>Hurn</surname><given-names>PD</given-names></name></person-group><year>2003</year><article-title>Estrogen and ischemic neuroprotection: an integrated view.</article-title><source>Trends Endocrinol Metab</source><volume>14(5)</volume><fpage>228</fpage><lpage>235</lpage><pub-id pub-id-type="pmid">12826329</pub-id></citation></ref><ref id="pone.0005153-Quintanilla1"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Quintanilla</surname><given-names>RA</given-names></name><name><surname>Munoz</surname><given-names>FJ</given-names></name><name><surname>Metcalfe</surname><given-names>MJ</given-names></name><name><surname>Hitschfeld</surname><given-names>M</given-names></name><name><surname>Olivares</surname><given-names>G</given-names></name><etal/></person-group><year>2005</year><article-title>Trolox and 17beta-estradiol protect against amyloid beta-peptide neurotoxicity by a mechanism that involves modulation of the Wnt signaling pathway.</article-title><source>J Biol Chem</source><volume>280(12)</volume><fpage>11615</fpage><lpage>11625</lpage><pub-id pub-id-type="pmid">15659394</pub-id></citation></ref><ref id="pone.0005153-ToranAllerand1"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Toran-Allerand</surname><given-names>CD</given-names></name><name><surname>Singh</surname><given-names>M</given-names></name><name><surname>Setalo</surname><given-names>G</given-names><suffix>Jr</suffix></name></person-group><year>1999</year><article-title>Novel mechanisms of estrogen action in the brain: new players in an old story.</article-title><source>Front Neuroendocrinol</source><volume>20(2)</volume><fpage>97</fpage><lpage>121</lpage><pub-id pub-id-type="pmid">10328986</pub-id></citation></ref><ref id="pone.0005153-Belcher1"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Belcher</surname><given-names>SM</given-names></name><name><surname>Zsarnovszky</surname><given-names>A</given-names></name></person-group><year>2001</year><article-title>Estrogenic actions in the brain: estrogen, phytoestrogens, and rapid intracellular signaling mechanisms.</article-title><source>J Pharmacol Exp Ther</source><volume>299(2)</volume><fpage>408</fpage><lpage>414</lpage><pub-id pub-id-type="pmid">11602649</pub-id></citation></ref><ref id="pone.0005153-Miller1"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>DB</given-names></name><name><surname>Ali</surname><given-names>SF</given-names></name><name><surname>O'Callaghan</surname><given-names>JP</given-names></name><name><surname>Laws</surname><given-names>SC</given-names></name></person-group><year>1998</year><article-title>The impact of gender and estrogen on striatal dopaminergic neurotoxicity.</article-title><source>Ann N Y Acad Sci</source><volume>844</volume><fpage>153</fpage><lpage>165</lpage><pub-id pub-id-type="pmid">9668673</pub-id></citation></ref><ref id="pone.0005153-Sawada1"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sawada</surname><given-names>H</given-names></name><name><surname>Ibi</surname><given-names>M</given-names></name><name><surname>Kihara</surname><given-names>T</given-names></name><name><surname>Urushitani</surname><given-names>M</given-names></name><name><surname>Honda</surname><given-names>K</given-names></name><etal/></person-group><year>2000</year><article-title>Mechanisms of antiapoptotic effects of estrogens in nigral dopaminergic neurons.</article-title><source>Faseb J</source><volume>14(9)</volume><fpage>1202</fpage><lpage>1214</lpage><pub-id pub-id-type="pmid">10834942</pub-id></citation></ref><ref id="pone.0005153-Sawada2"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sawada</surname><given-names>H</given-names></name><name><surname>Ibi</surname><given-names>M</given-names></name><name><surname>Kihara</surname><given-names>T</given-names></name><name><surname>Honda</surname><given-names>K</given-names></name><name><surname>Nakamizo</surname><given-names>T</given-names></name><etal/></person-group><year>2002</year><article-title>Estradiol protects dopaminergic neurons in a MPP&#x0002b;Parkinson's disease model.</article-title><source>Neuropharmacology</source><volume>42(8)</volume><fpage>1056</fpage><lpage>1064</lpage><pub-id pub-id-type="pmid">12128007</pub-id></citation></ref><ref id="pone.0005153-Kenchappa1"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kenchappa</surname><given-names>RS</given-names></name><name><surname>Diwakar</surname><given-names>L</given-names></name><name><surname>Annepu</surname><given-names>J</given-names></name><name><surname>Ravindranath</surname><given-names>V</given-names></name></person-group><year>2004</year><article-title>Estrogen and neuroprotection: higher constitutive expression of glutaredoxin in female mice offers protection against MPTP-mediated neurodegeneration.</article-title><source>Faseb J</source><volume>18(10)</volume><fpage>1102</fpage><lpage>1104</lpage><pub-id pub-id-type="pmid">15132975</pub-id></citation></ref><ref id="pone.0005153-Morissette1"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morissette</surname><given-names>M</given-names></name><name><surname>Jourdain</surname><given-names>S</given-names></name><name><surname>Al Sweidi</surname><given-names>S</given-names></name><name><surname>Menniti</surname><given-names>FS</given-names></name><name><surname>Ramirez</surname><given-names>AD</given-names></name><etal/></person-group><year>2007</year><article-title>Role of estrogen receptors in neuroprotection by estradiol against MPTP toxicity.</article-title><source>Neuropharmacology</source><volume>52(7)</volume><fpage>1509</fpage><lpage>1520</lpage><pub-id pub-id-type="pmid">17420033</pub-id></citation></ref><ref id="pone.0005153-Culmsee1"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Culmsee</surname><given-names>C</given-names></name><name><surname>Vedder</surname><given-names>H</given-names></name><name><surname>Ravati</surname><given-names>A</given-names></name><name><surname>Junker</surname><given-names>V</given-names></name><name><surname>Otto</surname><given-names>D</given-names></name><etal/></person-group><year>1999</year><article-title>Neuroprotection by estrogens in a mouse model of focal cerebral ischemia and in cultured neurons: evidence for a receptor-independent antioxidative mechanism.</article-title><source>J Cereb Blood Flow Metab</source><volume>19(11)</volume><fpage>1263</fpage><lpage>1269</lpage><pub-id pub-id-type="pmid">10566973</pub-id></citation></ref><ref id="pone.0005153-Dubal1"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dubal</surname><given-names>DB</given-names></name><name><surname>Shughrue</surname><given-names>PJ</given-names></name><name><surname>Wilson</surname><given-names>ME</given-names></name><name><surname>Merchenthaler</surname><given-names>I</given-names></name><name><surname>Wise</surname><given-names>PM</given-names></name></person-group><year>1999</year><article-title>Estradiol modulates bcl-2 in cerebral ischemia: a potential role for estrogen receptors.</article-title><source>J Neurosci</source><volume>19(15)</volume><fpage>6385</fpage><lpage>6393</lpage><pub-id pub-id-type="pmid">10414967</pub-id></citation></ref><ref id="pone.0005153-Wise2"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wise</surname><given-names>PM</given-names></name><name><surname>Dubal</surname><given-names>DB</given-names></name></person-group><year>2000</year><article-title>Estradiol protects against ischemic brain injury in middle-aged rats.</article-title><source>Biol Reprod</source><volume>63(4)</volume><fpage>982</fpage><lpage>985</lpage><pub-id pub-id-type="pmid">10993817</pub-id></citation></ref><ref id="pone.0005153-Wise3"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wise</surname><given-names>PM</given-names></name><name><surname>Dubal</surname><given-names>DB</given-names></name><name><surname>Wilson</surname><given-names>ME</given-names></name><name><surname>Rau</surname><given-names>SW</given-names></name><name><surname>Bottner</surname><given-names>M</given-names></name></person-group><year>2001</year><article-title>Minireview: neuroprotective effects of estrogen-new insights into mechanisms of action.</article-title><source>Endocrinology</source><volume>142(3)</volume><fpage>969</fpage><lpage>973</lpage><pub-id pub-id-type="pmid">11181507</pub-id></citation></ref><ref id="pone.0005153-Simpkins1"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Simpkins</surname><given-names>JW</given-names></name><name><surname>Yang</surname><given-names>SH</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Perez</surname><given-names>E</given-names></name><name><surname>Cai</surname><given-names>ZY</given-names></name><etal/></person-group><year>2004</year><article-title>Estrogen-like compounds for ischemic neuroprotection.</article-title><source>Stroke</source><volume>35</volume><issue>11 Suppl 1</issue><fpage>2648</fpage><lpage>2651</lpage><pub-id pub-id-type="pmid">15472107</pub-id></citation></ref><ref id="pone.0005153-Garcia1"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>C</given-names></name><name><surname>Calvo</surname><given-names>E</given-names></name><name><surname>Nieto</surname><given-names>A</given-names></name></person-group><year>2007</year><article-title>The transcription factor SOX17 is involved in the transcriptional control of the uteroglobin gene in rabbit endometrium.</article-title><source>J Cell Biochem</source><volume>102(3)</volume><fpage>665</fpage><lpage>679</lpage><pub-id pub-id-type="pmid">17427959</pub-id></citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>This work was supported by grants from CIBERNED (which was an initiative of the ISCIII), Plan Nacional DGCYT, SAF2006-12782-C03-01 and by an Institutional grant from the Fundacion Areces. OV was supported by MEC fellowship and CIBERNED contract. PM was supported by MEC fellowship. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group></back></article> 